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ABSTRACT 
 
The main purpose of this PhD project was to study the molecular bases of rare Mendelian diseases 
with Next Generation Sequencing approaches. 
To this aim, we enrolled at Umberto I General Hospital and Sapienza University of Rome four 
different families with a phenotype with a supposed genetic cause, in order to find the causative 
gene/genes. Clinical exome sequencing or whole exome sequencing was performed on selected 
subjects of each family. The supposed mode of inheritance defined the selection and the number of 
individuals to sequence, as well as the analytical approach to use. Sequencing data were analysed 
through a dedicated bioinformatic pipeline; variants were then filtered and prioritized according to 
several parameters, specific for each case. 
The selected variant/variants were validated through Sanger sequencing on the proband and on the 
other family members, to study their segregation in the family. 
The functional link between the candidate variant/variants and the phenotype was investigated, 
retrieving information from literature and online resources. 
In the four studied families the different approaches allowed us to identify the molecular causes of 
each disorder, with consequences on diagnosis, prognosis and genetic counselling. 
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1. INTRODUCTION 
 
1.1 Mendelian disorders and genetic tests 
  
Mendelian or monogenic diseases are caused by mutation in one gene. For this kind of disorders 
alternative genotypes fall into distinct and discrete phenotypes (Antonarakis and Beckmann, 2006). 
They are usually inherited in one of several patterns, depending on the location of the gene and 
whether one or two normal copies of the gene are needed for the disease phenotype to manifest: the 
expression of the mutated allele with respect to the normal one can be dominant, co-dominant or 
recessive; the five basic modes of inheritance for single-gene diseases are autosomal dominant, 
autosomal recessive, X-linked dominant, X-linked recessive and mitochondrial. To date, Mendelian 
diseases are estimated to be about 7,000 (Boycott et al., 2017). Clinically recognized Mendelian 
phenotypes compose a substantial fraction (~0.4% of live births) of known human diseases. If all 
congenital anomalies are included, ~8% of live births have a genetic disorder recognizable by early 
adulthood (Chong et al., 2015). 
Of approximately ~19,000 protein-coding genes predicted to exist in the human genome: variants 
causing Mendelian phenotypes have been identified in ~2,937 (~15.5%); genes underlying ~643 
Mendelian phenotypes (~3.38%) have been mapped but not yet identified; loss of function variants 
in up to ~30% of genes (~5,960) could result in embryonic lethality in humans; for a minimum of 
~52% of genes (~10,330), the impact in humans has not yet been determined. Collectively, ~16,063 
genes remain candidates for Mendelian phenotypes (Chong et al., 2015; Figure 1). 
 
                                
 
Figure 1. Relationship between human protein-coding genes and Mendelian phenotypes (Chong et al., 2015). 
 
Causative genetic variants can range in size from substitution, deletion or duplication of a single 
base pair to structural variants and to altered copy numbers of an entire chromosome (aneuploidy); 
in some cases, the penetrance of the disorder can be incomplete and the expressivity of individual 
	 5	
features can be variable. A proportion of variability in genetic diseases can also be attributed to 
locus heterogeneity and allelic heterogeneity; other important sources of variability include genetic 
variants at one or more other loci (modifiers) and environmental factors (Wright et al., 2018).   
In the past, the identification of Mendelian disease genes was carried out by linkage mapping and 
Sanger sequencing of candidate genes, which were selected because they reminded of genes 
associated with similar diseases, because the predicted protein function seemed relevant to the 
physiology of the disease or because a positional mapping approach pointed to these genes in a 
genomic region (Gilissen et al., 2012).   
Traditionally, there are two kinds of clinical genetic tests: high-resolution molecular single gene 
tests by Sanger sequencing and low-resolution genome-wide cytogenetic tests. The first ones are 
useful for the diagnosis of that conditions caused by just one or few genes, as cystic fibrosis or 
Duchenne muscular dystrophy; the second kind of tests can be used to diagnose aneuploidies and 
chromosome rearrangements (G-banded karyotype) or smaller structural variants (microarray) 
(Wright et al., 2018). 
Next generation sequencing (NGS) has revolutionized medical genetics through the high-
throughput massively parallel sequencing (Figure 2): it is accelerating the research about rare-
genetic diseases and it is facilitating clinical diagnosis and personalized medicine. In the last decade 
the capacity of NGS technology has increased, leading a throughput several orders of magnitude 
higher than Sanger sequencing (Goodwin et al., 2016), and its costs have come down considerably, 
facilitating the translation of sequencing from a research technology to a clinical tool. 
 
                      
 
Figure 2. Genome-wide assays used in clinical genetics: from traditional methods to whole genome sequencing.  
As the resolution of the test increases, the number of detectable variants, the diagnostic yield and likelihood of detecting incidental findings and 
variants of uncertain clinical significance increase too (Wright et al., 2018). 
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For a long time, a clinician first exhausted a battery of medical tests and then he turned to genetic 
testing only if the previous ones did not yield a definitive diagnosis or if there was a need to assess 
recurrence risk. Even positive genetic test results did not often change management of the patients. 
However, the introduction of NGS technology in the clinics and the increased knowledge in 
genetics let the clinicians begin altering the placement of genetic testing in the evaluation of their 
patients, saving time and money in identifying an aetiology.  
 
1.2 Next generation sequencing (NGS) technology  
 
Traditionally, NGS experiments have been performed using short-read sequencing (SRS) that 
produces reads from 100 to 400 bp in length, depending on the technology. SRS is based on library 
preparation by random fragmentation of input DNA, adapter ligation, amplification and massively 
parallel sequencing of adapter-ligated fragments (Caspar et al., 2018).   
There are two categories of short-read sequencing approaches: sequencing by ligation (SBL) and 
sequencing by synthesis (SBS). In SBL approaches (SOLiD and Complete Genomics), a labelled 
probe and anchor sequences hybridize to a DNA fragment and are ligated to an adjacent 
oligonucleotide through a DNA ligase. After ligation, the template is imaged and the emission 
spectrum of the fluorophore indicates which base or bases are complementary to a specific position 
inside the probe. The removal of the anchor–probe complex allows to regenerate the ligation site: a 
new cycle can begin (Goodwin et al., 2016; Figure 3). 
 
                                              
 
Figure 3. Sequencing by ligation methods: SOLiD (a) and Complete Genomics (b) (Goodwin et al., 2016). 
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SBS approaches can be classified either as cyclic reversible termination (CRT) or as single-
nucleotide addition (SNA). In these approaches a polymerase incorporates a nucleotide into an 
elongating strand producing a signal, such as a fluorophore or a change in ionic concentration. CRT 
approaches (Illumina, Qiagen; Figure 4) use similar terminator molecules to those used in Sanger 
sequencing, in which the ribose 3ʹ -OH group is blocked, preventing elongation. These molecules 
are individually labelled. After the incorporation of a single dNTP, unbound dNTPs are removed 
and the surface is imaged to identify which dNTP was incorporated at each cluster. The fluorophore 
and blocking group can then be removed and a new cycle can begin (Goodwin et al., 2016).  
 
                                             
 
Figure 4. Sequencing by synthesis (cyclic reversible termination approaches): Illumina (a) and Qiagen (b) (Goodwin et al., 2016). 
 
The Illumina technology reaches its maximum throughput with the HiSeq X Ten System, a set of 10 
HiSeq X platforms, which generates tens of thousands of high-quality and high-coverage genome 
sequences, breaking the $1000 barrier for 30× coverage of a human genome. 
SNA approaches (454, Ion Torrent; Figure 5) rely on a single signal to mark the incorporation of a 
dNTP into an elongating strand. For this reason, each nucleotide has to be added individually. The 
454 technology is based on pyrosequencing: when a dNTP is incorporated, an enzymatic cascade 
occurs, resulting in a bioluminescence signal; the Ion Torrent platform detects a change in pH: 
when a dNTP is incorporated, H+ ions are released (Goodwin et al., 2016). 
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Figure 5. Sequencing by synthesis (single-nucleotide addition approaches): 454 pyrosequencing (a) and Ion Torrent (b) (Goodwin et al., 2016). 
 
In both SBL and SBS approaches DNA is clonally amplified on a solid surface: thousands of 
identical copies of a DNA fragment in a defined area allow the signal to be distinguished from 
background noise. Different strategies can be used to generate clonal template populations: 
emulsion PCR [454 (Roche), SOLiD (Thermo Fisher), GeneReader (Qiagen), Ion Torrent (Thermo 
Fisher)], solid-phase bridge amplification (Illumina), in-solution DNA nanoball generation 
[Complete Genomics (BGI)]. Millions of individual SBL or SBS reaction centres are created, each 
with its own clonal DNA template and, in this way, millions of DNA molecules are sequenced 
in parallel (Goodwin et al., 2016). 
The main advantages of SRS are high-throughput, low per base cost and low raw-read error rate; 
the main disadvantage is the short-read length, which leads to reads alignment difficulties, that can 
cause misalignments, false-positive and false-negative variant calling (Caspar et al., 2018).  
These limitations can be overcome using long-read sequencing (LRS) or third-generation 
sequencing, which is a single-molecule sequencing PCR-free: the long reads facilitate unambiguous 
alignment to a reference genome through their increased ability to span large, complex, repetitive or 
homologous regions. However, LRS is not yet routinely applied due to its significantly lower 
throughput and higher per sample sequencing cost; furthermore, it has a high raw error rate of 
~10%. These errors can be minimized by increasing read depth and reading the template multiple 
times (Caspar et al., 2018). 
There are two main long-read technologies: single-molecule real-time sequencing approaches 
[PacBio and Oxford Nanopore Technologies (ONT); Figure 6] and synthetic approaches (Illumina 
synthetic long-read sequencing platform, 10X Genomics emulsion-based system; Figure 7), that 
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construct in silico long reads based on short-read technologies. Pacific Biosciences (PacBio) 
instrument has a flow cell with thousands of picolitre wells with transparent bottoms, called zero-
mode waveguides (ZMW), in which there is the DNA polymerase. There is a single circular 
molecule template per well and when the labelled nucleotide momentarily pauses during 
incorporation at the bottom of the ZMW, dNTP incorporation is continuously visualized with a 
laser and a camera system that records the colour and duration of emitted light. Each template is 
sequenced multiple times as a function of its length as the polymerase repeatedly traverses the 
circular molecule. Oxford Nanopore sequencers directly detect the DNA composition of a native 
single strand DNA molecule, which passes through a protein pore modifying the current that passes 
through the pore. These sequencers have flow cells with thousands of pores (Goodwin et al., 2016).  
 
                        
 
Figure 6. Real-time long-read sequencing approaches: Single-molecule real-time (SMRT) sequencing from Pacific Biosciences (PacBio; a) and 
Oxford Nanopore Technologies (ONT; b) (Goodwin et al., 2016). 
 
Synthetic long-read technology is based on a system of barcoding to associate fragments sequenced 
on existing short-read sequencers. The Illumina system partitions DNA into a microtitre plate and 
does not require specialized instrumentation; the 10X Genomics instruments use emulsion to 
partition DNA and require the use of a microfluidic instrument to perform pre-sequencing reactions 
(Goodwin et al., 2016). 
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Figure 7. Synthetic long-read sequencing approaches: Illumina (a) and 10X Genomics’emulsion-based sequencing (b) (Goodwin et al., 2016). 
 
1.3 Bioinformatic pipeline  
 
                              
 
Figure 8. Framework for variant discovery and genotyping from next-generation sequencing data (DePristo et al., 2011). 
 
After completing the sequencing run, raw reads data (FASTQ files) have to be processed (Figure 8): 
the first analysis step is to evaluate the quality of raw reads and to remove, trim or correct reads that 
do not meet the defined standards. During this step also adaptor sequences are removed (DePristo et 
al., 2011). The second step consists in the alignment of the reads to the reference genome, which is 
given in a FASTA format. Currently, there are two main sources for the human reference genome 
assembly: the University of Santa Cruz (UCSC) and the Genome Reference Consortium (GRC). 
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Both provide several versions of the human genome, at the moment versions hg19 and hg38 for the 
UCSC assembly and GRCh37 and GRCh38 for the GRC one. Both human assemblies are identical 
but differ with regards to their nomenclature (Pabinger et al., 2014). After the alignment, the 
duplicate reads are removed: indeed, during library amplification and sequencing process the same 
DNA molecules can be sequenced several times and the multiple reads can interfere with variant 
calling statistics. The output is a SAM (sequence alignment/map) file containing all retained reads 
(Pabinger et al., 2014). This format is commonly used to store next-generation sequencing 
alignments. SAM files can be easily converted to the BAM (binary alignment/map) format, that is a 
binary representation of the SAM. Initial alignments are refined by local realignment and then there 
is the step of base recalibration that assigns a well-calibrated probability to each base call (Pabinger 
et al., 2014).  
Two important parameters to evaluate a NGS experiment are coverage and depth: the empirical per-
base coverage represents the exact number of times that a base in the reference genome is covered 
by a high-quality aligned read from a given sequencing experiment; redundancy of coverage is also 
called the depth or the depth of coverage (Sims et al., 2014). 
The following step is variant calling, which consists in the identification of the DNA sequence 
variations relative to the reference genome. Variations that can be recognized are single-nucleotide 
variants (SNVs) and small insertion-deletions (Indels). The output file of this analysis is a Variant 
Calling File (VCF) (Van der Auwera et al., 2013). Then there is the functional annotation of the 
variants and the genes that harbour them (Pabinger et al., 2014), a process that places mutations 
identified by the variant calling step into their biological context (Salgado et al., 2016). The main 
objective of the annotation step is to gather substantial information at the variant and at the gene 
levels. At the variant level it includes data quality, genomic position, genotype, frequency in the 
general population, impact at the mRNA and protein levels, conservation of the affected protein 
residues among species, variant pathogenicity prediction and reported associations with diseases. At 
the gene level it includes the function of the gene, tissue expression pattern, involvement in 
pathways and in phenotypes/diseases (Salgado et al., 2016). Accurate annotation of variants is 
important to understand their functional effects and to select the most promising candidate 
pathogenic mutations. Accurate annotation of genes is critical to understand the functional 
associations of the genes with pathways in normal and disease states (Chakravorty and Hegde, 
2017). Finally, the variants are filtered based on quality criteria and prioritized, according to the 
specific disease, on the basis of pedigree information and the mode of inheritance, the localization 
of the variant, the mutation type, the frequency of the variant, the predicted impact of the variant on 
protein function and structure, the functional evidences and the evolutionary conservation of variant 
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nucleotide (Salgado et al., 2016). The aim of these two last steps is to combine different criteria to 
identify potentially candidate variants (Salgado et al., 2016). There are two options to proceed with 
the prioritization of the variants: one is to employ a semiautomatic prioritization system, which is a 
useful approach for example when the phenotype is clearly described using the proper phenotype 
ontology such as the Human Phenotype Ontology (HPO terms); the second one is to adopt a manual 
prioritization procedure based on expert knowledge about disease phenotype and gene functions. 
This approach can be greatly facilitated by the use of filtration tools (Salgado et al., 2016). 
 
1.4 Gene identification approaches 
 
When a rare phenotype is recurring in a family, the likelihood of a monogenic rare disease is high. 
The mode of inheritance influences the selection and the number of individuals to sequence, as well 
as the analytical approach to use (Boycott et al., 2013; Figure 9). 
 
                     
 
Figure 9. Gene identification approaches for different categories of rare diseases (Boycott et al., 2013). 
 
For autosomal recessive disorders, sib pair analysis is often needed to reduce the number of gene 
variants to one or few candidates. For this kind of diseases, compound heterozygous or 
homozygous variants should be searched in affected siblings and heterozygous variants in their 
unaffected parents. For X-linked recessive diseases, the favoured strategy is to analyse the two most 
remotely related male family members, looking for X-chromosome variants in carrier females and 
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in affected males. For autosomal dominant disorders, the approach is to analyse the two most 
remotely related family members, looking for shared heterozygous variants, which are absent in 
unaffected family members. Analysis of whole-exome sequencing data from unaffected parents and 
the affected child (trio analysis) is extremely useful for de novo variants, which are in a 
heterozygous state in the proband and absent in unaffected parents; comparison of these 
heterozygous variants between different families in which the probands have the same phenotype 
generally reduces these variants to a single candidate gene. The comparison of sequence data from a 
patient’s affected and unaffected tissues is frequently sufficient to identify mosaic disease-causing 
mutations (Boycott et al., 2013). 
 
1.5 NGS approaches 
 
The NGS technology allows to sequence a specific subset of genes (targeted sequencing, TS; 
clinical exome sequencing, CES), the exome (whole exome sequencing, WES) or the entire genome 
(whole genome sequencing, WGS) in a matter of hours to days, depending on the protocol and the 
platform used. 
The management of NGS data, the lack of understanding of the impact of most genetic variants on 
human health and disease and the amount of secondary findings which can be found during a 
genetic test are some of the parameters that a clinician has to consider before assigning a NGS test 
to patients. 
 
1.5.1 Targeted sequencing (TS) 
 
Targeted sequencing (TS) or gene panel sequencing allows to enrich only the coding regions of 
genes of interest for a specific disease or a diagnostic category (Table 1).  
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Table 1. Clinically available disease-targeted tests (Rehm, 2013). 
 
This strategy has some advantages:  
• it is cheaper than the other ones; 
• panels can have a much higher or often complete coverage of the genes they contain, 
because the gaps can be filled with supplemental Sanger sequencing and other 
complementary technologies (Rehm, 2013);  
• a targeted approach also allows for a deeper coverage of all phenotype-specific genes, 
providing a greater confidence in the variants detection (Jamuar and Tan, 2015). In order to 
use TS for clinical diagnostics, high-quality data are essential, i.e. not the mean on-target 
depth, but ideally all nucleotides are seen at a minimal read depth of 20x–40x (Weiss et al., 
2013). For this reason, a targeted approach is more efficient to reveal mosaic mutations than 
WES; 
• panels usually are used in laboratories with an extensive clinical experience with a particular 
disease and its causative genes, so these laboratories may be better able to prioritize variants 
in those genes and to understand their clinical significance (Rehm, 2013);  
• targeted sequencing minimizes the problems of incidental findings (Rehm, 2013); 
• depending on the enrichment strategy and the platform used, several hundred target genes 
can be sequenced for multiple patients in the same run. Data can also be analysed within a 
relatively short processing time (de Koning et al., 2015); 
• the size of the data files generated by panels is small and it is possible to store not only the 
variant files but also the FASTQ files for longer periods (Weiss et al., 2013). 
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However, this strategy has also some disadvantages:  
• as the other NGS approaches, it is prone to sequencing artefacts and Sanger sequencing of 
candidate variants is always recommended (Jamuar and Tan, 2015); 
• panels have to be continuously updated when new genes are identified (Jamuar and Tan, 
2015). 
For these reasons many laboratories have now shifted to performing WES and limiting the analysis 
to genes associated with phenotype and filling up the gaps with Sanger sequencing (in silico gene 
panels). Although this strategy is more expensive, it allows for re-analyse the data when new genes 
are discovered (Jamuar and Tan, 2015). 
 
1.5.2 Clinical exome sequencing (CES) 
 
Clinical exome sequencing is a technology that allows to sequence all the genes associated with 
diseases and it is being applied to a wide range of clinical presentations that require a broad search 
for causal variants across the spectrum of genetically heterogeneous Mendelian disorders (Lee H et 
al., 2014).  
The TruSight One Sequencing Panel (2014) provides comprehensive coverage of about 4,800 
disease-associated genes, while the TruSight One Expanded Sequencing Panel (2017) targets 
~1,900 additional genes with recent disease associations in the scientific literature 
(https://www.illumina.com/products/by-type/clinical-research-products/trusight-one.html).  
The analysis can be initially limited to only those genes that are relevant to the patient’s phenotype, 
but then it can be extended to a much broader gene set or even to the entire disease-associated 
exome (Rehm, 2013). This approach is simple as a disease-targeted test and it enables the 
laboratory to minimize test development and validation efforts (Rehm, 2013). 
 
1.5.3 Whole exome sequencing (WES) 
 
Whole exome sequencing is currently the most used approach for the discovery of those rare-
disease-causing genes that conventional approaches have failed to identify. It is estimated, in fact, 
that 85% of the disease-causing mutations is located in coding and functional regions of the 
genome. For this reason, sequencing of the complete coding regions (exome) can uncover the 
causes of a large number of rare genetic disorders as well as predisposing variants of common 
diseases and cancers.  
The initial proof-of-concept for using WES in rare-disease research came with the identification of 
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genes responsible for the dominant Freeman–Sheldon syndrome (OMIM #193700; Ng et al., 2009), 
recessive Miller syndrome (OMIM #263750; Ng et al., 2010) and dominant Schinzel–Giedion 
syndrome (OMIM #269150; Hoischen et al., 2010), respectively MYH3, DHODH and SETBP1. 
Then the discovery of disease-causing genes using WES has increased rapidly (Boycott et al., 2013; 
Figure 10). 
 
                                            
 
Figure 10. Rate of discovery of novel rare-disease-causing genes using whole-exome sequencing (Boycott et al., 2013). 
 
WES has been also used to identify the causative variants in several heterogeneous conditions, such 
as hearing loss, intellectual disabilities, autism spectrum disorders and retinitis pigmentosa 
(Rabbani et al., 2014). WES has been successfully deployed in the clinics too, appearing as the most 
cost-effective NGS approach (Jamuar and Tan, 2015). It is probably the most efficient technique for 
identifying de novo mutations in a parents-patient trio approach for heterogeneous disorders with 
very large numbers of putative causative genes (de Koning et al., 2015). 
Although WES is supposed to cover all the protein-coding regions of the genome, the overall 
coverage depends on the enrichment strategy used and it tends to be between 85-95% only. The 
reasons include poorly performing capture probes due to high GC content, sequence homology and 
repetitive sequences (Jamuar and Tan, 2015). Coverage is also heterogeneous probably because of 
the hybridization/capture and PCR-amplification steps required for the preparation of sequencing 
libraries for WES (Kebschull and Zador, 2015).  
Coverage of almost each nucleotide of interest is of major importance for the application of NGS 
technology in clinical diagnostics and sequence depth is, therefore, an important quality parameter 
in NGS applications. At a mean on-target read depth of 20x, which is commonly used in WES 
studies for diagnosing rare disorders for instance, one would miss 5–15% of the heterozygous and 
1–4% of the homozygous single nucleotide variants in the targeted regions (Meynert et al., 2013). 
An exome approach produces terabytes of data that demand major storage capacity (Weiss et al., 
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2013). On average, ~60,000 to 100,000 variants are detected during a WES experiment. These 
variants can be classified into pathogenic, benign and variants of uncertain significance (VUS). 
Pathogenic variants are those that adversely alter protein function and have either been reported 
previously in other affected individuals or have been shown to affect protein function in cellular or 
animal models. Benign variants or polymorphisms exist in a significant proportion of the population 
and account for the majority of the variants detected through NGS testing. VUS are variants that 
could possibly affect protein function based on in silico prediction, but they either have not been 
described in other individuals (affected or unaffected) or do not have any functional analysis in 
other model systems (Jamuar and Tan, 2015).  
Using WES, a single pathogenic variant can be detected about 20–36% of the time; in other cases, it 
is possible to either find multiple candidate variants or no candidate variant. If multiple candidate 
variants were detected, segregation analysis and/or functional analysis would help to determine the 
molecular aetiology. If no variants were detected, it would be possible that the causal variant is in a 
poorly covered region or outside protein-coding regions (Jamuar and Tan, 2015). WES is prone to 
sequencing artefacts and Sanger sequencing of candidate variants is always recommended (Jamuar 
and Tan, 2015). 
WES is not a useful approach for the identification of copy number variants (CNVs), due to the 
non-contiguous nature of the captured exons and to the extension of most CNVs beyond the regions 
covered by the exome kit (Belkadi et al., 2015). However, numerous methods have been developed 
to detect CNVs from exome sequencing data, like ExomeDepth (Plagnol et al., 2012), ExomeCopy 
(Love et al., 2011), XHMM (Fromer et al., 2012), cn.MOPS (Klambauer et al., 2012), ExomeCNV 
(Sathirapongsasuti et al., 2011), CoNVEX (Amarasinghe et al., 2013), EXCAVATOR (Magi et al., 
2013), CoNIFER (Krumm et al., 2012), CANOES (Backenroth et al., 2014), CODEX (Jiang et al., 
2015) and many others. Now there are also kits able to enrich for CNVs: one example is OneSeq 
Target Enrichment (Agilent, Santa Clara, USA), which consists of baits designed to detect CNVs 
and Loss of Heterozygosity (LOH) genome-wide down to 1 Mb and 10 Mb resolution, respectively. 
In addition, OneSeq includes user-defined baits for any Agilent exome, gene or custom panel or 
custom regions for Single Nucleotide Variants and Indels calling. 
Furthermore, during a WES experiment, secondary or incidental findings (IFs) could be detected. 
They can be defined as pathogenic or likely pathogenic alterations in genes that are not apparently 
relevant to the diagnostic indication for which the sequencing test was ordered. Different guidelines 
about incidental findings are followed in different countries. In the United States, for example, 
patients have always to be advised before the test that secondary findings may be detected and 
laboratories should report on incidental findings detected in a minimum set of 56 genes, selected by 
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the American College of Medical Genetics and Genomics (ACMG) (Green et al., 2013).  
 
1.5.4 Whole genome sequencing (WGS) 
 
Whole genome sequencing allows the most continuous sequence coverage and it permits to identify 
sequence variants throughout the genome. Because of the complexity and the greater cost of WGS, 
WES is currently the most used approach, even though WGS has a better diagnostic yield based on 
overall variant calling sensitivity and efficiency (lower coverage depth required for similar 
sensitivity), lack of bias and uniformity of coverage, features that have a great importance in a 
clinical setting where reliability and reproducibility of results are crucial (Lelieveld et al., 2015). 
Furthermore, a higher coverage increases the sensitivity for detecting copy number variants 
(Medvedev et al., 2010; Szatkiewicz et al., 2013) and the lack of allele biases improves the 
detection of somatic variations (Lelieveld et al., 2015). 
WGS is also slightly but significantly more powerful than WES for detecting variants in the regions 
covered by the exome kit, particularly for SNVs. WGS is prone to sequence artefacts too and 
Sanger sequencing of candidate variants is always recommended (Jamuar and Tan, 2015). In 
addition, WGS is certainly more appropriate for detecting CNVs because it covers all breakpoints 
and detects variations in RNA- and protein-coding exome regions not covered by the exome 
(Belkadi et al., 2015).  
However, the costs (WGS currently costs two to three times as much as WES, but most of the costs 
of WGS are directly related to sequencing whereas WES costs are mainly due to the capture kit; 
Belkadi et al., 2015) and analysis time (4 million variants are identified) still seriously limit 
implementation in routine diagnostics (Sun et al., 2015), as the problems related to incidental 
findings and data storage. 
To date, intronic, intergenic and regulatory sequence variants are difficult or impossible to interpret, 
but in the future they will add a superior value to WGS data and probably in silico WGS-based gene 
panels will be used in routine diagnostics. 
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1.6 NGS approaches and their diagnostic rate  
 
                                 
 
Figure 11. Balance between the diagnostic potential of a sequencing strategy and its feasibility and cost (Wright et al., 2018). 
 
There is a balance between the diagnostic potential of a sequencing strategy and its feasibility and 
cost (Figure 11). Trio-based WGS is the approach with the highest diagnostic yield, but it is also the 
most demanding and expensive one regarding the informatics approach. Since 85% of the disease-
causing mutations is located in coding and functional regions of the genome, the use of WES 
approach only slightly lowers the diagnostic yield (for example in severe intellectual disability from 
~42% for WGS to ~40% for WES), but hugely reduces the cost. Moreover, although moving from a 
family trio-based approach to a proband-only approach reduces costs and practical problems, it 
substantially reduces also the diagnostic yield (to ~28%), because de novo status or phase can not 
be directly assigned to determine from which parent the variants were inherited. Gene panels and 
single genes sequencing are the most common approaches, but the rate of diagnosis varies 
considerably depending on the patient’s phenotype (Wright et al., 2018). 
Testing a single gene or a small number of genes may be preferable when the disease is 
phenotypically and/or genetically homogeneous; for phenotypically and/or genetically 
heterogeneous conditions, many hundreds of genes may need to be tested through NGS 
technologies. Genetic heterogeneity, in fact, increases as phenotypic specificity decreases: the less 
specific the phenotype associated with a disease is, the more likely it is to be caused by variants in 
many different genes (Wright et al., 2018; Figure 12). 
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Figure 12. Genetic heterogeneity increases as phenotypic specificity decreases (Wright et al., 2018). 
 
1.7 NGS guidelines 
 
1.7.1 The American College of Medical Genetics and Genomics (ACMG) guidelines  
 
ACMG recommends that the terms “mutation” and “polymorphism”, which have been used widely 
leading to confusion because of the incorrect assumption of their pathogenic and benign effect 
respectively, should be replaced by the term “variant” with the following modifiers:  
- pathogenic (class V): the sequence variation has been previously reported and recognized 
as causative of the disorder;  
- likely pathogenic (class IV): the sequence variation has not been previously reported, but it 
is inside a known disease gene;  
- uncertain significance (VUS; class III): the sequence variation is unknown or expected to 
be related to a clinical presentation;  
- likely benign (class II): the sequence variation has not been previously reported, but it is 
probably not causative of the pathology;  
- benign (class I): the sequence variation has been already reported and documented as 
neutral variant (Di Resta et al., 2018). 
For a given variant, the user has to select criteria based on the evidence observed; then the criteria 
are combined according to some scoring rules that allow to classify the variant (Table 2). When a 
variant does not fulfill criteria or the evidence for benign and pathogenic is conflicting, it defaults to 
uncertain significance (Richards et al., 2015). 
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Table 2. The criteria that allow to classify the variants are organized by the type of evidence as well as their strength for  
a benign (left side) or a pathogenic (right side) assertion (Richards et al., 2015). 
 
When a laboratory finds a variant in a gene without a validated association to the patient’s 
phenotype, it is a gene of uncertain significance (GUS). It can occur when a gene has never been 
associated with any patient phenotype or when the gene has been associated with a different 
phenotype from that under consideration. Additional evidence would be required to support the 
association of the gene to the disease (Richards et al., 2015).  
The standard gene variant nomenclature maintained and versioned by the Human Genome Variation 
Society (HGVS) should be used. Laboratories should note the version used in their test methods; 
clinical reports should include sequence references to ensure unambiguous naming of the variant at 
the DNA, RNA and protein levels. Only specific exceptions to the HGVS nomenclature are 
supported (Richards et al., 2015). 
ACMG recommends also to clinicians to report incidental findings in some relevant genes 
associated with a set of disorders, on the bases of clinical validity and utility. No technology can be 
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used to measure the size of tandem repeats accurately: for this reason, some disorders are not 
included. The laboratories have to actively look for the specified kinds of variant in the genes listed 
in the recommendations. Clinicians have to contextualize any incidental finding for the patient in 
light of personal and family history, physical examination and other relevant findings. The variants 
that have to be reported are those fitting two categories: “sequence variation is previously reported 
and is a recognized cause of the disorder” (Known Pathogenic, KP), “sequence variation is 
previously unreported and is of the type which is expected to cause the disorder” (Expected 
Pathogenic, EP). Laboratories should not ensure a depth of coverage for these genes equivalent to 
molecular testing for primary indication (Green et al., 2013). 
Incidental variants should be reported for any clinical sequencing conducted on a constitutional (but 
not tumor) tissue and incidental variants should be reported regardless of the age of the patient 
(Green et al., 2013). 
The clinician has to provide a comprehensive pre- and post-test counselling to the patient (Green et 
al., 2013). Whenever clinical sequencing is ordered, the clinician should discuss with the patient the 
possibility of incidental findings and the laboratory should report incidental findings in the genes 
listed in the recommendations without reference to patient’s preferences. However, the patient has 
the right to decline clinical sequencing if he judges the risks of eventual incidental findings to 
outweigh the benefits of the test (Green et al., 2013). 
 
1.7.2 The Italian Society of Human Genetics (SIGU) guidelines 
 
Patient’s phenotypic characterization is crucial for the choice of the molecular test and for the 
analysis of the identified variants. The Italian Society of Human Genetics (SIGU) recommends that 
different approaches should be applied in different situations (Documento Commissione SIGU-
NGS, 2016; www.sigu.net): 
- in case of phenotype characterized by a low genetic heterogeneity and caused by 
small genes, it is better to use conventional molecular methods;  
- in case of phenotype characterized by a high genetic heterogeneity or caused by very 
long genes, it is suggested to use NGS platforms, in order to decrease time and costs; 
- in case of phenotype characterized by a high genetic heterogeneity, but caused in 
most cases by mutations in the same genes, targeted sequencing (gene panels) is 
suggested; 
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- targeted sequencing is also recommended in case of mosaic mutations; 
- in case of phenotype characterized by an increasing genetic heterogeneity, it is 
suggested to perform WES and limit the analysis to genes associated with phenotype 
(in silico gene panels); 
- when a diagnostic hypothesis can not be formulated it is suggested to perform WES, 
looking for known or new genes. 
Genetic counselling is always recommended before and after the test (Documento Commissione 
SIGU-NGS, 2016; www.sigu.net): 
- before the test, the proband has to subscribe an informed consent, which explains 
exhaustively what kind of results he can obtain from the test (IFs, VUS, information 
about parents) and allows him to decide which results he agrees to know. IFs can be: 
deleterious variants, which have an immediate clinical utility; known or presumed-
deleterious variants, that, despite being reliably associated with a disease or relevant 
trait, are not medically actionable; variants which have no known medical relevance 
and do not have a clinical utility (Berg et al., 2011). The proband has to be supported 
in the decision to wether receive or not information about the variants of the first two 
categories; variants of the third category should not be communicated; 
- a post-test counselling is necessary for the communication of the results and 
eventually of the IFs. Only those incidental findings decided by the patient should be 
communicated. However, sometimes the patient’s right to decide on his own could 
not coincide with the principles of medical deontology. It can happen when IFs are 
related to diseases for which it is possible to realize therapeutic or preventive 
measures or in the case of a disease involving also relatives. At this stage, the 
clinician can also propose further investigations, if it deemed necessary; 
- in the case of oncological test, the possibility to find variants associated with cancer 
predisposition has to be discussed during the counselling and a specific informed 
consent is used. 
Quality requirements are specified (Documento Commissione SIGU-NGS, 2016; www.sigu.net): 
- it is important to use a standardized terminology to describe the patient’s phenotype 
(HPO terms) as it allows to share information accurately; 
- it is important to standardize parameters and minimum requirements for each test 
within different laboratories; 
- the medical report should be composed of only one page, with some technical 
attachments; 
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- if the test is an in silico panel, one attachment should include the analysed gene 
subset with the average coverage of each gene; the limits of the panel and the 
bioinformatic pipeline have to be specified together with any supplementary 
technique used; 
- positive results have to be confirmed with Sanger sequencing and it is necessary to 
verify the coverage of the region through a specific browser, like Integrative 
Genomics Viewer (IGV); 
- minimum parameters of coverage have to be established. 
The big amount of data produced by NGS techniques causes a lot of storage problems. However, 
laboratories should conserve for a long time at least the most important files of the NGS workflow: 
the FASTQ file, which contains the reads produced by the sequencer; the BAM file, which contains 
the reads aligned to the reference genome; the VCF file, which contains the variants compared to 
the reference sequence. An important feature of NGS tests, in fact, is the temporary nature of their 
results, related to the development of the scientific knowledge: for this reason, they should be re-
evaluated periodically (Documento Commissione SIGU-NGS, 2016; www.sigu.net). 
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2. AIM OF THE STUDY 
 
The main purpose of this PhD project was to study Mendelian diseases with different Next 
Generation Sequencing approaches, selecting the most appropriate NGS technology and analysis 
workflow to investigate the molecular bases of four different genetic disorders, in order to improve 
their diagnosis and prognosis and to support genetic counselling. 
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3. MATERIALS AND METHODS 
 
3.1 Subjects selection  
 
In this work we enrolled at Umberto I General Hospital and Sapienza University of Rome four 
different families in which a phenotype with a supposed genetic cause was recurrent, in order to 
identify the causative gene/genes with the most appropriate NGS technology and data analysis 
approach. Informed consents for DNA storage and genetic analyses were obtained for each subject 
or his parents; permission to publish photographs was given for all subjects reported in this work. 
 
Family A: the index patient (III:6) was a 16-year-old girl from a small town in central Italy, who 
was referred to the Department of Oral and Maxillo Facial Sciences of Sapienza University of 
Rome. The patient showed a bilateral absence of permanent maxillary canines and anamnestic 
analysis suggested the presence of several family members also affected by canine anomalies. 
Clinical standardized assessment, including panoramic radiographs, oral photographs and 
anamnestic data, was performed on fourteen members of the family by a trained orthodontist. 
Exome enrichment and massively parallel sequencing were performed on the genomic DNA of 
subjects III:1, III:4 and III:6 (pedigree in Figure 13).  
 
Family B: the proband (III:2) was a 5-year-old boy affected by an isolated form of brachydactyly 
with features of type A1 (OMIM #112500) and type C (OMIM #113100), as his maternal 
grandfather (I:1), while his mother (II:2) showed a very mild phenotype. The proband was also 
referred to the medical geneticist because of his short stature. Detailed information on pedigree, 
anamnesis, clinical assessment and radiographs were collected for all subjects. Exome enrichment 
and massively parallel sequencing were performed on the genomic DNA of subjects I:1 and III:2 
(pedigree in Figure 21). 
 
Family C: the proband (II:3) was a 4-year-old girl affected by corpus callosum hypoplasia, 
daughter of a healthy Italian mother and a healthy Chinese father. The mother underwent 
amniocentesis and CGH-array during prenatal period, with negative results. The proband had a 
healthy sister (II:1). We analysed also the fetal DNA from a previously interrupted pregnancy: the 
fetus (II:2) was a female and showed corpus callosum agenesis and other severe malformations. 
Before the voluntary interruption of pregnancy, a CGH-array was performed identifying a de novo 
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microduplication 17q12 (31,635,490-33,323,002) x3 of uncertain significance. 
Clinical exome sequencing was performed on the genomic DNA of the trio, I:1, I:2 and II:3 
(pedigree in Figure 30).  
 
Family D: the proband (II:2) was a fetus with corpus callosum agenesis and other severe 
malformations. SNP-array was performed before the voluntary interruption of pregnancy and 
revealed a degree of homozygosity of 1% in the fetus, excluding parental consanguinity. A previous 
pregnancy was interrupted because of a male fetus (II:1) with the Dandy-Walker syndrome (OMIM 
%220200) and hydrocephalous. Exome enrichment and massively parallel sequencing were 
performed on the genomic DNA of II:2 (pedigree in Figure 36). 
 
3.2 DNA extraction 
 
The DNA was extracted from circulating leukocytes, saliva, buccal mucosa cells or hair bulbs using 
the Gentra Puregene Blood Kit (Qiagen, Hilden, Germany). 
 
To extract DNA from circulating leukocytes the protocol “DNA purification from whole blood or 
bone marrow using the Gentra Puregene Blood Kit” was used. Erythrocytes were lysed and 
discarded; then, leukocytes were lysed with an anionic detergent in the presence of a DNA 
stabilizer, to limit the activity of DNases. RNA was then removed by treatment with a RNA 
digesting enzyme. Other contaminants, such as proteins, were removed by salt precipitation. The 
genomic DNA was then recovered by precipitation with isopropanol and the pellet washed using 
70% ethanol. Finally, the genomic DNA was dissolved in hydration solution (1 mM EDTA, 10 mM 
Tris·CI pH 7.5).  
 
To extract DNA from saliva the protocol “DNA purification from body fluid using the Gentra 
Puregene Blood Kit” was used. The cells were lysed with an anionic detergent in the presence of a 
DNA stabilizer, to limit the activity of DNases. Puregene Proteinase K was added in order to digest 
contaminating proteins. RNA was then removed by treatment with a RNA digesting enzyme. Other 
contaminants, such as proteins, were removed by salt precipitation. The genomic DNA was then 
recovered by precipitation with isopropanol and the pellet washed using 70% ethanol. Finally, the 
genomic DNA was dissolved in hydration solution (1 mM EDTA, 10 mM Tris·CI pH 7.5).  
 
To extract DNA from buccal mucosa cells collected through a buccal brush the protocol “DNA 
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purification from a buccal brush using the Gentra Puregene Blood Kit” was used. The buccal brush 
was placed inside an anionic detergent in the presence of a DNA stabilizer, to limit the activity of 
DNases. Puregene Proteinase K was added in order to digest contaminating proteins. The brush was 
removed and the solution was centrifugated to recover as much liquid as possible. RNA was then 
removed by treatment with a RNA digesting enzyme. Other contaminants, such as proteins, were 
removed by salt precipitation. The genomic DNA was then recovered by precipitation with 
isopropanol and the pellet washed using 70% ethanol. Finally, the genomic DNA was dissolved in 
hydration solution (1 mM EDTA, 10 mM Tris·CI pH 7.5).  
To extract DNA from hair, the hair bulbs were cut and dissolved in an anionic detergent in the 
presence of a DNA stabilizer, to limit the activity of DNases. Puregene Proteinase K was added in 
order to digest contaminating proteins. RNA was then removed by treatment with a RNA digesting 
enzyme. Other contaminants, such as proteins, were removed by salt precipitation. The genomic 
DNA was then recovered by precipitation with isopropanol and the pellet washed using 70% 
ethanol. Finally, the genomic DNA was dissolved in hydration solution (1 mM EDTA, 10 mM 
Tris·CI pH 7.5).  
To accurately assess sample quantity and quality, the extracted DNA was quantified through the 
NanoDrop spectrophotometer. A 260/280 ratio of ~ 1.8 is generally accepted as “pure” for DNA; if 
the ratio is appreciably lower, it may indicate the presence of protein, phenol or other contaminants 
that absorb strongly at or near 280 nm. The 260/230 value for a “pure” DNA is often higher than the 
respective 260/280 value and is commonly in the range of 1.8 – 2.2; if the ratio is appreciably 
lower, it may indicate the presence of contaminants which absorb at 230 nm, as EDTA, 
carbohydrates and phenol. 
 
3.3 NGS techniques: whole exome and clinical exome sequencing 
 
The extracted genomic DNA was processed for the sequencing experiment through different steps: 
- library preparation: the genomic DNA was enzymatically or physically 
fragmented and an in vitro shotgun library was constructed through the ligation with 
adaptors to the ends of the fragments and amplified; 
- targeted enrichment: targeted enrichment was performed by an hybridization 
capture approach: the fragments were hybridized to biotinylated baits in the presence 
of blocking oligonucleotides that were complementary to the adaptors; the 
hybridized fragments were recovered by biotin-streptavidin-based pulldown; 
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- indexing and pooling: the targeted enrichment was followed by an adapter ligation 
with specific barcodes; all the samples were pooled together and the libraries were 
sequenced in parallel.  
 
The whole exome or the clinical exome of the selected subjects were sequenced using different 
technologies and kits for the targeted enrichment: 
 
 
 
Table 3. NGS platforms and kits for the targeted enrichment used for whole exome or clinical exome sequencing. 
 
The whole exome sequencing of III:1 and III:4 of the family A was carried out by BGI (Shenzen, 
China) and the exome of III:6 by Complete Genomics (Mountain View, CA, United States), on 
DNA extracted from circulating leukocytes; the whole exome sequencing of I:1 and III:2 of the 
family B was performed at Casa Sollievo della Sofferenza Hospital (Foggia, Italy) on DNA 
extracted from circulating leukocytes; the clinical exome sequencing of I:1, I:2 and II:3 of the 
family C was performed at the CSS-Mendel Institute (Rome, Italy) on DNA extracted from 
circulating leukocytes; the whole exome sequencing of II:2 of the family D was performed at 
CRIBI (Centro di Ricerca Interdipartimentale per le Biotecnologie Innovative) Genomics (Padua, 
Italy) on DNA extracted from amniotic fluid cells (technical details about sequencing in Table 3).  
 
3.4 Data analysis 
 
Sequencing data were processed through several steps: at first the removal of the sequences of the 
adaptors and the alignment of the reads to the reference genome (UCSC GRCh37/hg19) were 
performed through the Burrows-Wheeler Aligner (Li and Durbin, 2009), a software package for 
mapping low-divergent sequences against a large reference genome, in order to determine the exact 
position of each read on the human genome. As a following step, the duplicate reads were labelled 
through Picard's MarkDuplicates (http://broadinstitute.github.io/picard). Duplicates arose from 
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artefacts during PCR amplification (PCR duplicates) or resulted from a single amplification cluster, 
incorrectly detected as multiple clusters by the optical sensor of the sequencing instrument (optical 
duplicates). Because all the duplicate reads were sampled from the same DNA molecule, they gave 
an uneven representation of that molecule compared to the others and they biased the SNV calling. 
Picard's MarkDuplicates identified duplicates as reads that mapped with identical coordinates and 
orientations. After the removal of duplicate reads, Genome Analysis Toolkit (GATK) (McKenna et 
al., 2010), a collection of command-line tools for analysing high-throughput sequencing data, 
performed at first the base recalibration step through GATK Base Recalibrator, which assigned an 
error to each base. After that, GATK HaplotypeCaller performed the variant calling, which 
consisted in the identification of the DNA sequence variations relative to the reference genome 
(Single Nucleotide Variations or SNVs and small Indels). Finally, functional annotation of variants 
was performed using ANNOVAR (Wang K et al., 2010) and SNPEff (Cingolani et al., 2012) tools, 
to annotate SNVs and small Indels and to analyse their functional consequence on transcripts and 
proteins and their frequency in population database (1000 Genomes Project, dbSNP, ExAC, 
gnomAD). As a transcript reference dataset we used RefSeq. We added further information from 
different online resources on variants and genes, related to clinical information (ClinVar, OMIM), 
in-silico pathogenicity predictions (e.g., Eigen, CADD, DANN, PolyPhen-2, SIFT), conservation 
(e.g., PhyloP and PhastCons), functional descriptions of genes, gene expression and gene 
interaction information (e.g., Gene Ontology, KEGG pathways, tissue specific gene expression and 
Variation Intolerance Score).  
 
Sequencing data were analysed depending on the NGS technology used; different versions of the 
tools were used: 
 
 
 
 
Table 4. Tools for NGS data analysis. 
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3.5 Selection of candidate variants (filtering and prioritization) 
 
At first, the variants were filtered based on quality criteria and their effect: only high-quality 
variants and those with an effect on the coding sequence and splice site regions were retained. Then 
variants were prioritized, according to the specific disease, on the basis of pedigree information and 
the mode of inheritance, the localization of the variant, the mutation type, the frequency of the 
variant, the predicted impact of the variant on protein function and structure, the functional 
evidences, the evolutionary conservation of variant nucleotide and the annotation in databases.  
Different parameters and thresholds were used for each phenotype:  
 
Family A: we prioritized variants using a public database (ExAC V.0.3.1) to retain novel and 
annotated changes with an unknown frequency or having a minor allele frequency (MAF) ≤ 5% and 
occurring with a frequency ≤ 10% in an in-house database, which includes approximately 600 
exomes. Then we analysed the functional impact of variants by Combined Annotation Dependent 
Depletion (CADD) (V.1.3), a tool for scoring the deleteriousness of DNA variants, using as 
threshold a value of 10 (Kircher et al., 2014). We drew up a list of known genes for isolated and 
syndromic phenotypes characterized by hypodontia and/or related dental anomalies. We used search 
terms such as “hypodontia”, “primary failure of tooth eruption”, “selective tooth agenesis”, 
“oligodontia”, “anodontia” and “agenesis of permanent teeth” to retrieve information from literature 
(PubMed), mutation database (HGMD-Human Genome Mutation Database, 
http://www.hgmd.cf.ac.uk/ac/) and phenotype databases  (OMIM-Online Mendelian Inheritance in 
Man, https://www.omim.org; HPO-Human Phenotype Ontology, http://human-phenotype-
ontology.github.io). Then, we analysed the WES data in order to identify and prioritize variants 
segregating according to different inheritance patterns, and matching at least one of the following 
criteria: known causative variants, variants in known genes, variants in genes functionally related to 
teeth development and variants predicted deleterious using CADD scoring system. Finally, we 
analysed the potentially causative variants in terms of gene function, gene expression, animal 
models, and phenotype, retrieving information from several databases, i.e. OMIM-Online 
Mendelian Inheritance in Man (https://www.omim.org), HPO-Human Phenotype Ontology 
(http://human-phenotype-ontology.github.io), MGI-Mouse Genome Informatics 
(http://www.informatics.jax.org), ZFIN-Zebrafish Information Network (https://zfin.org), and 
literature (PubMed). 
 
Family B: we prioritized the variants to retain only those with a frequency ≤ 4% in gnomAD 
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database (V.2.0) and with a CADD (V.1.3) score ≥ 10 (Kircher et al., 2014), predicted to have a 
high functional impact on the protein. We drew up a list of known genes for isolated and syndromic 
brachydactylies; then, we prioritized the variants hypothesising an X-linked transmission or an 
autosomal dominant transmission with variable expressivity and matching at least one of the 
following criteria: known causative variants, variants in known genes and variants predicted 
deleterious using CADD scoring system.  
 
Family C: we prioritized the variants to retain only those with a frequency ≤ 3% in gnomAD 
database (V.2.0) and those with a CADD score (V.1.3) ≥ 10 (Kircher et al., 2014). We drew up a 
list of known genes for corpus callosum dysgenesis; then we prioritized the variants, looking for a 
de novo heterozygous variant or homozygous/compound heterozygous variants and variants 
matching at least one of the following criteria: known causative variants, variants in known genes, 
variants in genes functionally related to brain development and variants predicted deleterious using 
CADD scoring system. We further analysed potentially causative variants on the basis of different 
parameters, as gene function and gene expression. 
 
Family D: we prioritized the variants to retain only those with a frequency ≤ 3% in gnomAD 
database (V.2.0) and those with a CADD score (V.1.3) ≥ 10 (Kircher et al., 2014). We drew up a 
list of known genes for corpus callosum dysgenesis; then, we prioritized the variants, looking for an 
autosomal recessive or a X-linked variant and variants matching at least one of the following 
criteria: known causative variants, variants in known genes, variants in genes functionally related to 
brain development and variants predicted deleterious using CADD scoring system. We further 
analysed potentially causative variants on the basis of different parameters, as gene function and 
gene expression. 
 
3.6 Variants validation 
 
Sanger sequencing was used to validate selected candidate variants and to perform segregation 
analyses. 
Variants were PCR-amplified by using GoTaq G2 Flexi DNA polymerase (Promega, Madison, WI, 
USA) and custom primers (Tables 5, 6 and 7). 
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Table 5. Primers used to amplify selected variants. 
 
                                          
 
Table 6. PCR protocol with GoTaq G2 Flexi DNA polymerase. 
 
                                                                
 
Table 7. PCR cycling parameters. 
 
The amplicons were checked through 2% agarose gel electrophoresis and purified using MSB Spin 
PCRapace (Stratec Molecular, Berlin, Germany).  
Sanger sequencing was performed by using the ABI BigDye Terminator Sequencing Kit (V.3.1) 
(Applied Biosystems, Foster City, CA, USA) as per the manufacturer's protocol (Tables 8 and 9). 
 
                          
 
Table 8. Sanger sequencing protocol with Big Dye 3.1. 
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Table 9. Sequencing reaction cycling parameters. 
 
Dye removal from cycle-sequencing reactions was carried on with MSB Spin PCRapace (Stratec 
Molecular, Berlin, Germany). Sanger sequencing was performed with automated capillary 
sequencers: the ABI Prism 3500 Genetic Analyzers (Applied Biosystems, Foster City, CA, USA) or 
the 3130/3130xl Genetic Analyzers (Applied Biosystems, Foster City, CA, USA).  
Sequence electropherograms were analysed by using ChromasPro (V.1.7.5; Technelysium Pty Ltd, 
Brisbane, Australia). 
 
3.7 Modeling of the nucleotidyltransferase domain of FKTN (family D) 
 
The in silico modeling of the nucleotidyltransferase domain of human FKTN (hFKTN) protein 
(NP_001073270.1) was made through the Phyre software, in collaboration with Professor 
Alessandro Paiardini, Sapienza University of Rome. 
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4. RESULTS 
 
4.1 Family A 
 
The family was composed of three generations (Figure 13): the index patient (III:6) showed a 
bilateral absence of permanent maxillary canines; the other members of the family showed different 
maxillary canine anomalies, including canine agenesis, either monolateral or bilateral, canine 
impaction and canine ectopic eruption, phenotypes that seem to be different manifestations of the 
same disorder (Figure 14). 
We performed WES of three cousins of the third generation, one for each branch of the family.  
 
                 
 
Figure 13. Pedigree of the family with canine anomalies; black lines indicate individuals for whom DNA was available for the molecular analyses; 
the arrows indicate individuals who underwent whole exome sequencing (WES). 
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Figure 14. Clinical photographs and panoramic radiographs of dentitions of six affected family members. Subject III:6 (a-b): the index patient shows 
congenital absence of 1.3 and 2.3 and the persistence of the left upper deciduous canine. Panoramic radiograph shows the agenesis of permanent 
maxillary canines and root resorption of left deciduous canine. All third molars are present. Subject III:5 (c-d): agenesis of 1.3. Panoramic radiograph 
shows the persistence of the right upper deciduous canine with root resorption; 3.5 anomalous radicular distal tip is observed. Subject II:6 (e-f): 
palatal bilateral maxillary impacted canines and persistence of the upper deciduous canines are observed. Subject III:7 (g-h): palatal bilateral 
maxillary impacted canines and persistence of the upper deciduous canines are observed. Subject III:1 (i): impacted canine 2.3; persistence of the left 
upper deciduous canine and 1.2 microdontic lateral incisor are shown. Subject III:4 (j): ectopic  eruption 1.3. Panoramic radiograph shows the 
orthodontic treatment. Mild crowding of maxillary arch can also be observed. The asterisks indicate the missing, impacted or ectopically erupting 
permanent maxillary canines (Barbato et al., 2018). 
 
We obtained the following whole exome sequencing data output: 
 
                                      
 
Table 10. Whole exome sequencing data output. 
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We assumed that the phenotype in this family fit an autosomal dominant segregation model with 
incomplete penetrance in males and variable expressivity in the first two branches; we supposed a 
more complex segregation pattern in the third branch, due to a possible contribution of both paternal 
and maternal origin. 
After bioinformatic analysis of WES data, we obtained 64,852, 66,389 and 103,815 total variants in 
III:1, III:4 and III:6, respectively. 
Then, we filtered the exome variants using several criteria (see Material and Methods section) and 
we obtained: 13,144, 13,213 and 12,494 non synonymous/frameshift/splicing (-8/+3) variants in 
III:1, III:4 and III:6, respectively; 1,735, 1,708 and 2,345 variants with unknown ExAC frequency 
or MAF ≤ 5% in III:1, III:4 and III:6, respectively; 1,119, 1,071 and 2,061 variants with a frequency 
≤ 10% (58/587) in the in-house database in III:1, III:4 and III:6, respectively; 648, 680 and 1,234 
variants with combined annotation dependent depletion (CADD) score ≥10 in III:1, III:4 and III:6, 
respectively. 
Variants, either shared or not by the three affected cousins, were filtered and prioritized. To this 
aim, as a first step, we created a list of 96 genes involved in dental anomalies, using information 
from several databases (OMIM-Online Mendelian Inheritance in Man, HGMD-Human Genome 
Mutation Database, HPO-Human Phenotype Ontology, PubMed) and we analysed single WES data 
looking for candidate variants in genes previously associated with dental anomalies; in a second 
step of the analysis, we prioritized candidate genes on the basis of their involvement in teeth 
development and the sharing among the three cousins. 
Using the previous described criteria we selected the following variants: 
 
 
 
Table 11. Candidate variants identified through WES approach. 
 
The first step of the analysis led to the identification in subject III:6 (bilateral canine agenesis) of 
two missense variants in EDARADD and COL5A1, previously associated with tooth agenesis and a 
syndromic phenotype including dental anomalies, respectively. 
The EDARADD variant (NM_145861.2: c.308C>T; NP_665860.2: p.Ser103Phe; rs114632254) was 
found also in her sister (III:5; monolateral canine agenesis) and her mother (II:6; bilateral canine 
maxillary inclusion) (Figures 15 and 20). 
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Figure 15. Electropherograms showing genotypes of patients and unaffected individuals for EDARADD variant (Barbato et al., 2018). 
 
The COL5A1 variant (NM_000093.4: c.1588G>A; NP_000084.3: p.Gly530Ser; rs61735045) was 
found in subjects III:5 (monolateral canine agenesis), III:6 (bilateral canine agenesis) and III:2 
(unaffected); it segregated from the paternal grandmother (I:2; monolateral upper left palatal 
impacted canine) (Figure 16 and 20). 
 
 
Figure 16. Electropherograms showing genotypes of patients and unaffected individuals for COL5A1 variant (Barbato et al., 2018). 
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The second step of the analysis didn’t lead to the identification of interesting variants in genes 
functionally related to teeth development, shared by subjects III:1, III:4 and III:6. We therefore 
focused on variants shared by subjects III:1 (monolateral upper left palatal impacted maxillary 
canine and right lateral incisor microdontia) and III:4 (monolateral upper right ectopic labial 
eruption of maxillary canine) and we found three missense variants in RSPO4 (NM_001029871.3: 
c.317G>A; NP_001025042.2: p.Arg106Gln; rs6140807), T (NM_003181.3: c.1013C>T; 
NP_003172.1: p.Ala338Val; rs117097130) and NELL1 (NM_001288713.1: c.1244G>A; 
NP_001275642.1: p.Arg415His; rs141323787) genes. 
The RSPO4 variant was found in subjects III:1 (monolateral upper left palatal impacted canine), 
III:4 (monolateral upper right ectopic labial eruption of canine), I:2 (monolateral upper left palatal 
impacted canine) and III:3 (unaffected) (Figures 17 and 20). 
 
 
 
Figure 17. Electropherograms showing genotypes of patients and unaffected individuals for RSPO4 variant (Barbato et al., 2018). 
 
The T variant was found in subjects III:1 (monolateral upper left palatal impacted canine), III:4 
(monolateral upper right ectopic labial eruption of canine), I:2 (monolateral upper left palatal 
impacted canine), III:2 (unaffected) and III:3 (unaffected) (Figures 18 and 20). 
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Figure 18. Electropherograms showing genotypes of patients and unaffected individuals for T variant (Barbato et al., 2018). 
 
The NELL1 variant was found in subjects III:1 (monolateral upper left palatal impacted canine), 
III:4 (monolateral upper right ectopic labial eruption of canine), I:2 (monolateral upper left palatal 
impacted canine), III:2 (unaffected) and III:3 (unaffected) (Figures 19 and 20). 
 
Figure 19. Electropherograms showing genotypes of patients and unaffected individuals for NELL1 variant (Barbato et al., 2018). 
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Segregation analysis of all the analysed variants was summarized in the following genealogic tree:  
 
 
 
Figure 20. Variants identified in EDARADD, COL5A1, RSPO4, T and NELL1 genes in analysed family members; aminoacidic substitutions are 
reported for all tested variants; “wt” indicates wild type allele; “ND” indicates genotypes that have not been experimentally determined. 
 
4.2 Family B 
 
The family was composed of three generations (Figure 21): a proband (III:2) affected by an isolated 
form of brachydactyly with features of type A1 (OMIM #112500) and type C (OMIM #113100) 
(Figures 22 and 23), as his maternal grandfather (Figures 24 and 25), and his mother with a very 
mild phenotype of the hands (Figures 26 and 27).  
We analysed the pedigree and performed WES of the proband and the grandfather. 
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Figure 21. Pedigree of the family with brachydactyly; black lines indicate individuals for whom DNA was available for the molecular analyses; the 
arrows indicate individuals who underwent whole exome sequencing (WES). 
 
                           
 
Figure 22. Clinical photographs of the proband (III:2), affected by an isolated form of brachydactyly with features of type A1 and type C. 
 
                                                 
 
Figure 23. Radiograph of the left hand of the proband (III:2), affected by an isolated form of brachydactyly with features of type A1 and type C. The 
arrows show the absence of an intermediate phalanx in the index, the presence of an anomalous intermediate phalanx in the ring finger and the 
delayed ossification of the carpal bones. 
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Figure 24. Clinical photographs of I:1, affected by an isolated form of brachydactyly with features of type A1 and type C. 
 
                                           
 
Figure 25. Radiograph of the hands of I:1, affected by an isolated form of brachydactyly with features of type A1 and type C. The arrows show the 
subluxation of the metacarpophalangeal joint of the index, the presence of an intermediate phalanx of reduced size of the ring finger especially on the 
left and the absence of the intermediate phalanx of the index of the right hand. 
 
                                
 
Figure 26. Clinical photographs of II:2, who shows a single palmar crease and the length of the intermediate phalanxes slightly lower than normal. 
 
                                                              
 
Figure 27. Radiograph of the left hand of II:2, who shows a single palmar crease and the length of the intermediate phalanxes slightly lower than 
normal. The arrows show the shortening of intermediate phalanxes in particular of the second and fifth fingers. 
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We obtained the following whole exome sequencing data output: 
 
                                  
 
Table 12. Whole exome sequencing data output. 
 
After bioinformatic analysis of WES data, we obtained 61,840 total variants. 
We then filtered the exome variants using several criteria (see Material and Methods section) and 
we obtained: 13,579 high-quality variants with an effect on the coding sequence and splice site 
regions; 1,644 variants with frequency ≤ 4% (the most frequent brachydactylies have a frequency of 
2%) in gnomAD database or with unknown frequency; 1,077 variants with a CADD (Combined 
Annotation Dependent Depletion V.1.3) score ≥ 10, predicted to have a high functional impact on 
the protein. We then prioritized the variants hypothesising an X-linked transmission, obtaining 11 
variants, or an autosomal dominant transmission with variable expressivity, obtaining 261 variants.  
Then we focused on genes known to cause isolated or syndromic brachydactylies and we selected 
as the most interesting a frameshift variant in GDF5 (NM_000557.4: c.157dupC; NP_000548.2: 
p.Leu53Profs*41; rs778834209) that had a gnomAD frequency of 0.000866%; the CADD scoring 
system predicted a high functional impact (22.8).  
Sanger sequencing confirmed the presence of the heterozygous variant in GDF5 in the proband and 
the grandfather and disclosed its presence also in the mother; the other analysed family members 
resulted not carrier of the variant (Figure 28). 
 
                    
Figure 28. Electropherograms showing genotypes of patients and unaffected individuals for GDF5 variant. 
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Segregation analysis of the analysed variant was summarized in the following genealogic tree: 
                                    
 
Figure 29. Variant identified in the GDF5 gene in analysed family members; the aminoacidic substitution is reported; “wt” indicates wild type allele; 
“ND” indicates the genotype that has not been experimentally determined. 
 
4.3 Family C 
 
The family was composed of two generations (Figure 30): the proband (II:3), daughter of a healthy 
Italian mother and a healthy Chinese father, was affected by corpus callosum hypoplasia (Figure 
31), discovered first through ultrasound and after confirmed through fetal magnetic resonance. Fetal 
karyotype and CGH-array, performed after amniocentesis, gave negative results. The proband has a 
healthy sister; the fetus from a previous interrupted pregnancy was female and showed corpus 
callosum agenesis and other severe malformations. Before the voluntary interruption of pregnancy, 
a CGH-array was performed identifying a de novo microduplication 17q12 (31,635,490-
33,323,002) x3 of uncertain significance. 
We performed clinical exome sequencing of the proband and her parents (trio). 
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Figure 30. Pedigree of the family with corpus callosum dysgenesis; black lines indicate individuals for whom DNA was available for the molecular 
analyses; the arrows indicate individuals who underwent clinical exome sequencing (CES). 
 
 
 
Figure 31. Fetal magnetic resonance of II:3 at 25+4 and 32 weeks. Sagittal (A), coronal (B) and transversal (C) section. 
 
We obtained the following clinical exome sequencing data output: 
 
                                
 
Table 13. Clinical exome sequencing data output. 
 
After bioinformatic analysis of CES data, we obtained 42,062 total variants in the trio. 
We filtered the clinical exome variants using several criteria (see Material and Methods section) and 
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we obtained: 4,317 high-quality variants in the proband with an effect on the coding sequence and 
splice site regions; 552 variants with a frequency ≤ 3% or with unknown frequency in gnomAD 
database; 335 variants with a CADD score ≥ 10.  
Then we prioritized the variants, obtaining 7 de novo heterozygous, 3 homozygous and 31 
compound heterozygous. We also performed a prioritization step based on the phenotype through 
the Phenolyzer tool. Potentially causative variants were further analysed based on different 
parameters, as gene function and gene expression.  
We found a candidate de novo nonsense variant in ARX (NM_139058.2: c.922G>T; NP_620689.1: 
p.Glu308*), which was not reported in gnomAD database; it was recently annotated in ClinVar (ID 
522170) as pathogenic; the CADD scoring system predicted a high functional impact (36).  
Sanger sequencing confirmed the presence of the variant in the proband and disclosed the presence 
of the same variant also in the fetus (Figure 32).  
       
 
 
Figure 32. Electropherograms showing genotypes of patients and unaffected individuals for ARX variant; these sequences were obtained from DNA 
extracted from blood (I:1, I:2, II:1 and II:3) and from amniotic fluid (II:2). 
 
This result led to suppose a gonadal or gonosomal mosaicism in one of the parents for the causative 
ARX variant. For this reason we performed Sanger sequencing also on DNA extracted from saliva 
and from hair bulbs (Figures 33 and 34) that did not disclose the presence of the variant in the 
parents. 
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Figure 33. Electropherograms showing genotypes of patients and unaffected individuals for ARX variant; these sequences were obtained from DNA 
extracted from saliva. 
 
                                     
 
Figure 34. Electropherograms showing genotypes of unaffected individuals for ARX variant; these sequences were obtained from DNA extracted 
from hair bulbs. 
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Sequence analysis results in different tissues were summarized in the following genealogic tree: 
                           
 
Figure 35. Variant identified in the ARX gene in different tissues of analysed family members; the aminoacidic substitution is reported; “wt” indicates 
wild type allele; “ND” indicates genotypes that have not been experimentally determined. 
 
4.4 Family D  
 
The family was composed of two generations (Figure 36): the proband (II:2) was a fetus with 
corpus callosum agenesis and other severe malformations (Figure 37). Fetal karyotype and SNP-
array, performed after amniocentesis, gave negative results; SNP-array data demonstrated 
homozygosity levels of 1% in the fetus, excluding parental consanguinity. Corpus callosum 
agenesis was discovered first through ultrasound and after confirmed through fetal magnetic 
resonance. A previous pregnancy was interrupted because of a male fetus with the Dandy-
Walker syndrome (OMIM %220200) and hydrocephalous. 
We analysed the pedigree and performed WES of the proband (II:2). 
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Figure 36. Pedigree of the family with corpus callosum dysgenesis; black lines indicate individuals for whom DNA was available for the molecular 
analyses; the arrow indicates the individual who underwent whole exome sequencing (WES). 
 
 
 
Figure 37. Fetal magnetic resonance of II:2. Sagittal (A), coronal (B) and transversal (C) section. 
 
After bioinformatic analysis of WES data, we obtained 46,610 total variants. 
We filtered the exome variants using several criteria (see Material and Methods section) and we 
obtained: 11,301 high-quality variants with an effect on the coding sequence and splice site regions; 
1,132 variants with a frequency ≤ 3% or with unknown frequency in gnomAD database; 713 
variants with a CADD (Combined Annotation Dependent Depletion V.1.3) score ≥ 10. The 
phenotype, in fact, is very rare and severe and we supposed it has to be caused by a mutation with a 
high functional impact on the protein.  
Then we prioritized the variants hypothesising an autosomal recessive transmission, obtaining 42 
variants, or an X-linked transmission, obtaining 21 variants, or an autosomal dominant 
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transmission, obtaining 658 variants. We also performed a prioritization step based on the 
phenotype through the Phenolyzer tool. Potentially causative variants were further analysed on the 
bases of different parameters: we studied gene function, gene expression and animal models that we 
retrieved from several databases, as OMIM-Online Mendelian Inheritance in Man, HPO-Human 
Phenotype Ontology and MGI-Mouse Genome Informatics.  
We selected as the most interesting a homozygous variant in FKTN (NM_006731.2: c.898G>A; 
NP_006722.2: p.Gly300Arg; rs909129168), which had no frequency in gnomAD database; the 
CADD scoring system predicted a high functional impact (34).  
Sanger sequencing confirmed the presence of the homozygous variant in the proband; both the 
parents resulted heterozygous (Figure 38).  
 
 
 
Figure 38. Electropherograms showing genotypes of patients and unaffected individuals for FKTN variant. 
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Segregation analysis of the analysed variant was summarized in the following genealogic tree: 
 
                                   
 
Figure 39. Variant identified in the FKTN gene in analysed family members; the aminoacidic substitution is reported; “wt” indicates wild type allele; 
“ND” indicates the genotype that has not been experimentally determined. 
 
4.4.1 Modeling of the nucleotidyltransferase domain of FKTN  
 
In order to test the pathogenicity of the variant, a structural modeling of FKTN was performed. 
Domain analysis of human FKTN (hFKTN) protein (NP_001073270.1) showed that Gly300 is part 
of a nucleotidyltransferase (NT) fold comprising residues 278-411 of hFKTN. Modeling of residues 
278-411 of hFKTN (based on PDB Codes 4WQL, nucleotidylyltransferase ANT(2")-Ia and 4FO1, 
adenylyltransferase LnuA) showed that this domain follows the α1-β1-α2-β2-X-β4-β3 NT fold 
topology and that binding of nucleoside triphosphate groups (NTGs) is stabilized by two Mg2+ ions 
in the active site. Due to similarities in the active sites of LnuA, ANT(2″)-Ia and hFKTN, it was 
possible to identify the putative nucleotide binding site in hFKTN (Figures 40 and 41).  
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Figure 40. Comparison between the model of hFKTN (residues 278-411; cyan) and its structural template 4WQL (green). The two Mg2+ ions are 
displayed as spheres. Conserved Asp residues coordinating the ions are shown as sticks. The aminoglycoside Kanamycin is also shown as green 
sticks. The position of Gly300 is shown in pink. 
 
 
 
 
 
 
 
 
Figure 41. Comparison between the model of hFKTN (residues 278-411; cyan) and its structural template 4WQL (green). The two Mg2+ ions are 
displayed as spheres. Conserved Asp residues coordinating the ions are shown as sticks. The aminoglycoside Kanamycin is also shown as green 
sticks. The mutation of Gly300 with Arg is shown in white sticks. The position of the Arg residue corresponds to the predicted binding site of ATP. 
 
 
This comparison identified a cleft just beside the active site and sugar binding site in which the 
Gly300 residue resides. 
The analysis of the active site of hFKTN was highly consistent with a catalytic mechanism 
involving a nucleophilic attack on the α-phosphate of the NTGs by the substrate 2″-OH of sugar 
moieties, for subsequent transfer to α-dystroglycan. Replacing Gly300 with an Arg residue was 
therefore predicted to have steric hindrance effects that prevent the NTGs from binding the cleft, 
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abolishing the activation of the sugar moiety. The latter activity is required for the glycosylation of 
α-dystroglycan in skeletal muscle.  
Thus, Gly300Arg is likely responsible for a reduced activation of the sugar moieties, which in turn 
impairs transfer to α-dystroglycan.  
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5. DISCUSSION 
 
We studied the molecular bases of four different phenotypes with a supposed genetic cause through 
different NGS technologies and data analysis approaches. 
The selection of the experimental strategy, the number of subjects to sequence and the data analysis 
approach were dictated by some considerations on the diagnostic potential of each sequencing 
strategy and its feasibility and cost.  
Indeed, some criteria can significantly influence the choice of which NGS test has to be performed. 
They include the diagnostic rate, the possibility to re-evaluate the NGS data periodically, the 
management of NGS data, the functional interpretation of coding and non coding variants and the 
number of secondary findings. Moreover, there are some features that influence the choice and that 
depend on each specific case, e.g. the supposed mode of inheritance, the available samples and the 
information about the phenotype object of the study. For this reason, a deep and as much as 
accurate as possible knowledge about the potentiality of each NGS approach is essential to solve the 
molecular bases of a phenotypic picture. In the studied cases, we selected a different NGS strategy 
(i.e. whole exome or clinical exome sequencing) and different family members to sequence (i.e. the 
most distant family members, trio or singleton) according to considerations related to the observed 
phenotype and the hypothesized segregation pattern. The adopted experimental and data analysis 
strategies allowed to identify the molecular bases of phenotypes involving different systems (i.e. 
teeth, limbs and central nervous system) and belonging to different clinical pictures. 
To study the molecular bases of the complex phenotypes regarding canine agenesis and eruption 
anomalies in the family A, we used a WES approach on three first degree cousins. We selected an 
exome sequencing strategy as the pedigree analysis suggested a significant genetic component 
underlying the phenotype but with a complex segregation pattern. Different data analyses, based on 
different shared genetic causes, allowed to identify several candidate variants potentially involved 
in the pathogenetic mechanisms.  
To find the cause of the isolated brachydactyly observed in family B, we used a WES approach on 
the proband and his grandfather, looking for shared variants in the exome. We selected this strategy 
as isolated brachidactilies are a group of very heterogeneous limb anomalies, with different and not 
completely characterized molecular bases.  
To find the cause of the corpus callosum anomaly observed in the proband of family C, we chose a 
trio based approach, as the segregation pattern of the causative variant was not known. We 
performed a clinical exome sequencing, using an enrichment kit that included 171 on a total of 180 
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genes reported in literature as causative of corpus callosum malformations. 
To investigate the molecular bases of the recurrent phenotype observed in the family D, we 
performed WES only of the proband, because the phenotype suggested a recessive disorder. The 
malformation was at first defined as an isolated Dandy-Walker malformation, a rare anomaly for 
which molecular causes have not yet been recognized. 
 
5.1 Family A 
 
Dental agenesis is one of the most common human dental abnormalities: its prevalence, excluding 
third molars, ranges between 0.15% and 16.2% (Rakhshan, 2015). This condition may be classified 
as “oligodontia”, which consists of the absence of more than six teeth (excluding third molars), or 
“hypodontia”, which consists of the absence of one to six teeth.  
It may occur either as isolated condition or in syndromic phenotypes and in both familial and 
sporadic cases (Nieminen, 2009); both genetic and environmental factors are supposed to contribute 
to its pathogenesis. 
Several genes of few cell signaling pathways have been associated with isolated hypodontia, that 
seems to be transmitted as a dominant or recessive trait: PAX9 (Stockton et al., 2000), EDA (Tao et 
al., 2006), MSX1 (Vastardis et al., 1996), AXIN2, EDARADD (Bergendal et al., 2011), LRP6 
(Massink et al., 2015), WNT10A (Kantaputra and Sripathomsawat, 2011), GREM2 (Kantaputra et 
al., 2015), BMP4, BMP2 (Mu et al., 2012), WNT10B (Yu et al., 2016), PTH1R (Decker et al., 2008), 
EDAR (Arte et al., 2013) and SMOC2 (Alfawaz et al., 2013); mutations in WNT10A have been also 
reported as associated with the isolated agenesis of the permanent maxillary canine (Kantaputra et 
al., 2014).  
Another human dental abnormality is tooth impaction: the maxillary permanent canine is the second 
most frequent impacted tooth after the third molar, with a reported prevalence of 1-2% (Sajnani, 
2015). This could be due to a perturbation of tooth eruption and several contributing factors have 
been suggested including localized, systemic and genetic causes (Becker and Chaushu, 2015; 
Leonardi et al., 2003; Leonardi et al., 2009; Lombardo et al., 2007; Mercuri et al., 2013; Peck et al., 
1994) (Figure 42).  
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Figure 42. Tooth development is regulated by conserved signaling pathways (FGF, BMP, SHH, WNT, TNF). The signals mediate interactions 
between the oral ectoderm and mesenchyme and regulate the expression of key transcription factors (shown in the boxes) (Thesleff, 2006). 
 
The peculiar aspect of the studied family is the occurrence of several members with a variable 
phenotype that specifically involved maxillary canines, including agenesis, inclusion and ectopic 
eruption, without any other dental or extra-dental associated feature. The only exception is 
represented by the subject III:1, who shows a microdontic lateral incisor (1.2) placed on the 
opposite side of the impacted maxillary canine (2.3). Interesting to note, the ectopic labial eruption 
of maxillary canine observed in patients II:3 and III:4 is not due to inadequate arch space permitting 
the exclusion of the mechanical effect as the cause of eruption disorder. 
The exclusively female expression of the phenotypes, which appears to be characterized by 
incomplete penetrance in males, could be related to the strong difference in the prevalence of 
maxillary canine impaction between females and males (Ericson and Kurol, 1986), which could be 
caused by an earlier dentition development in the former (Rutledge and Hartsfield, 2010); however, 
it might be also due to the skewed proportion of females in the family tree (11 females vs 4 males). 
Canine anomalies are regarded as complex traits, but this uncommon family suggests a significant 
genetic contribution to these phenotypes: they might either represent different manifestations of the 
same basic disorder or they might share, in part, a molecular basis. In the first two branches of the 
family four members with impacted or ectopic erupted canines are present: a transmission of the 
trait according to an autosomal dominant segregation model, with incomplete penetrance and 
variable expressivity, is suggested by the evidence that ectopic eruption may be a manifestation of 
the impaction (Peck et al., 1994) and that both buccally and palatally displaced canines share 
similar etiologies (Sajnani and King, 2012). A more complex segregation pattern could occur in the 
third branch of the family, due to a possible concomitant paternal and maternal contribution.  
To date, only very few studies report Next Generation Sequencing strategies to study orodental 
pathologies, in particular canine anomalies (Massink et al., 2015; Ockeloen et al., 2016; Prasad et 
al., 2016; Salvi et al., 2016; Yamaguchi et al., 2017).  
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WES approach on three first degree cousins allowed to identify a heterozygous mutation in the 
EDARADD gene (NM_145861.2: c.308C>T; NP_665860.2: p.Ser103Phe; rs114632254) in two 
subjects with the most severe phenotype (i.e. canine agenesis). The variant was transmitted by the 
mother, who is not related to the family and presents a phenotype of bilateral impacted canines. 
EDARADD codes for a protein that interacts with EDAR, a death domain receptor required for hair, 
teeth and the development of other ectodermal derivatives. EDARADD is expressed in epithelial 
cells during the formation of hair follicles and teeth. Indeed, mutations in EDARADD have been 
associated with ectodermal dysplasias (OMIM #614940, #614941), characterized by defective 
development of hair, teeth and eccrine sweat glands (van der Hout et al., 2008). p.Ser103Phe variant 
has been previously associated with isolated oligodontia, including canine teeth, and is predicted to 
be functionally relevant (Arte et al., 2013; Bergendal et al., 2011; Salvi et al., 2016). EDARADD 
mutation carriers in this family did not show symptoms of ectodermal origin other than teeth 
dysgenesis. This finding suggests the involvement of the EDA signaling pathway in isolated 
oligodontia and confirms the considerable variation in clinical expression of EDARADD mutations. 
The most severe phenotype of subjects III:5 and III:6 could be caused by the concurrent 
contribution of paternally inherited DNA variants at other loci. In fact, the association of the 
p.Ser103Phe EDARADD variant with other mutations in genes related to teeth development has 
been already reported in isolated oligodontia, suggesting addictive effects of other pathways, e.g. 
the WNT signaling pathway (Arte et al., 2013; Salvi et al., 2016).  
Consistent with this hypothesis, a COL5A1 variant (NM_000093.4: c.1588G>A; NP_000084.3: 
p.Gly530Ser; rs61735045) was identified in subjects with canine agenesis (III:5 and III:6), 
segregating from the paternal affected grandmother (I:2). COL5A1 codes for a component of type V 
collagen particularly expressed in tendons. The variant localizes to the “interrupted collagenous 
region” of the protein and is predicted to interfere with the correct folding of the COL2 domain 
(Symoens et al., 2011). Haploinsufficiency of COL5A1 is a cause of Ehlers-Danlos syndrome 
(OMIM #130000), where dental anomalies, including hypodontia of permanent teeth and delayed 
eruption, are a common feature. Previously described cases suggest that this substitution causes a 
recessive form of Ehlers-Danlos syndrome (Giunta et al., 2002). The Gly530Ser change was 
previously reported as a disease modifying variant in Ehlers-Danlos syndrome type 1 (Steinmann 
and Giunta, 2000) and also as a biallelic causative mutation, with heterozygous parents showing 
subtle clinical signs (Giunta et al., 2002). None of the mutation carriers in the analysed family 
showed symptoms of connective disorder. However, it should be noted that the clinical significance 
of this variant has not been definitely established as there are conflicting interpretations of its 
pathogenicity (https://www.ncbi.nlm. nih.gov/clinvar/variation/38863). 
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According to a supposed dominant segregation model with incomplete penetrance and variable 
expressivity, several shared candidate variants in genes functionally related to tooth morphogenesis 
were identified in the two analysed subjects affected by canine eruption anomalies (III:1 and III:4). 
Potential harmful missense variants were identified in RSPO4 (NM_001029871.3: c.317G>A; 
NP_001025042.2: p.Arg106Gln; rs6140807), T (NM_003181.3: c.1013C>T; NP_003172.1: 
p.Ala338Val; rs117097130) and NELL1 (NM_001288713.1: c.1244G>A; NP_001275642.1: 
p.Arg415His; rs141323787) genes.  
RSPO4 codes for a member of the R-spondin protein family that has essential roles in vertebrate 
development and is expressed in the dental papilla (Pemberton et al., 2007). RSPO4 is a secreted 
protein that may be involved in activation of WNT/β-catenin signaling pathway. It is mutated in 
inherited anonychia (OMIM #206800), a rare autosomal recessive condition characterized by the 
absence or severe hypoplasia of nails. The p.Arg106Gln variant is positioned in the Furin-like 
repeat two domain of the protein, which is required for β-catenin stabilization (Ishii et al., 2008).  
The T gene codes for Brachyury, a transcription factor placed downstream of the WNT/β-catenin 
signaling pathway (Arnold et al., 2000) that binds to a specific DNA element, the palindromic T-
site. It binds through a region in its N-terminus, called the T-box, and effects transcription of genes 
required for mesoderm formation and differentiation. Murine models demonstrated that this gene is 
involved in establishing notochord cell identity and differentiation, and in the organization of the 
axial development (Herrmann, 1992). Diseases associated with T include Sacral Agenesis with 
Vertebral Anomalies (OMIM #615709) and Neural Tube Defects (OMIM #182940). The 
p.Ala338Val substitution lies in the second transactivation domain (Kispert et al., 1995) and has 
been previously associated with variable vertebral phenotypes, including multiple regional vertebral 
segmentation defects (Ghebranious et al., 2008).  
NELL1 codes for a cytoplasmic protein that contains epidermal growth factor (EGF)-like repeats: 
Nel-like molecule-1 (Nell-1) is a secreted heterotrimeric protein that plays an important role in 
osteoblast differentiation, bone formation and regeneration; it may be involved in cell growth 
regulation and differentiation. It is a protein strongly expressed in neural tissue, encoding epidermal 
growth factor-like domains suggesting its specificity for the craniofacial region. The expression 
patterns during tooth development suggest that it plays an important role in tooth morphogenesis 
(Tang et al., 2013).  
The WES data and segregation analyses of the family pointed to two different signaling pathways 
as responsible for the dental phenotypes, one of them (i.e. EDA) for the canine agenesis, and the 
other (i.e. WNT) for the less severe canine eruption anomalies.  
Further functional research on the mechanisms through which EDA and WNT pathways regulate 
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tooth morphogenesis and eruption is warranted to shed light on the pathogenesis of tooth agenesis.  
 
5.2 Family B 
 
The term brachydactyly is derived from the ancient Greek (brachy-: short; dactylos: digit) and 
indicates shortening of the hands and/or feet digits due to a lack or an abnormal development of 
phalanges, metacarpals, or both. It may occur as an isolated trait or as part of a syndrome (Temtamy 
and Aglan, 2008). According to the skeletal involvement, the isolated brachydactyly forms have 
been categorized in the groups A–E (Figure 43), including several subgroups. However, there is a 
considerable phenotypic overlap.  
 
                        
 
Figure 43. Clinical features of non-syndromic brachydactylies. Schematics showing bone and tissue involvement are shown on top. Middle row 
shows typical clinical features of hands. The corresponding X-ray figures are shown below (modified from Mundlos, 2009). 
 
The isolated forms usually occur as autosomal dominant traits and show variable expressivity and 
incomplete penetrance (Mundlos, 2009). Brachydactyly may be also associated with other hand 
malformations, such as syndactyly, polydactyly, reduction defects or symphalangism (Temtamy and 
Aglan, 2008); it can also occur as part of a syndrome and in bone dysplasias, as hand foot genital 
syndrome (HFGS; OMIM #140000), Robinow syndrome (RS; OMIM #268310), Acromesomelic 
chondrodysplasia with genital anomalies (OMIM #609441), Grebe type acromesomelic dysplasia 
(OMIM #200700), Hunter-Thompson type acromesomelic dysplasia (OMIM #201250), Du Pan 
type acromesomelic dysplasia (OMIM #228900) and Feingold or oculodigitoesophagoduodenal 
syndrome (OMIM #164280) (Mundlos, 2009). Many brachydactylies as well as the acromesomelic 
dysplasias are caused by mutation in various components of the BMP pathway and its modulators 
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(Mundlos, 2009).  
Despite many descriptions of these phenotypes in literature, there are no unanimously definite 
clinical or radiological criteria to assess the type of brachydactyly affecting a patient and the 
relative weight of the single features is not determined.  
The family we studied is composed of three generations: the proband is a 5-year-old boy affected by 
an isolated form of brachydactyly with features of type A1 (OMIM #112500) and type C (OMIM 
#113100), characterized by long proximal phalanx of finger, delayed ossification of carpal bones, 
short metacarpal, aplasia/hypoplasia of the middle phalanges of the hand, abnormality of the distal 
and the middle phalanges of the toes and clinodactyly of the 5th finger, as his maternal grandfather, 
who shows an isolated brachydactyly with the same characteristics; both of them have only one ring 
finger of the normal length; the proband was also referred to the medical geneticist because of his 
short stature, which is a relatively common but inconstant feature in some isolated or syndromic 
brachydactylies. His mother shows a mild phenotype: single palmar crease; length of the 
intermediate phalanxes slightly lower than normal.  
To find the cause of the isolated brachydactyly in this family, we used a WES approach on the 
proband (III:2) and his grandfather (I:1). Through this approach we identified a heterozygous 
variant in the GDF5 gene (NM_000557.4: c.157dupC; NP_000548.2: p.Leu53Profs*41; 
rs778834209). 
GDF5 gene is predominantly expressed in long bones during embryonic development; in the adult, 
it is expressed in fibroblasts and salivary glands. This gene encodes for growth and differentiation 
factor 5, a secreted ligand of the TGF-β (transforming growth factor-beta) superfamily of proteins; 
ligands of this family bind various TGF-β receptors leading to recruitment and activation of SMAD 
family transcription factors that regulate gene expression. 
The biological role of GDF-5 in vivo became first apparent from the genetic analysis of the 
brachypodism mice (bp), in which the length and the number of bones in the limbs were altered 
(Storm et al., 1994). These studies also led to the discovery of GDF-6 and -7 (Storm et al., 1994). 
Loss of function mutations in GDF5 reduce the signaling through the BMPR1B receptor and result 
in loss of an element (brachydactyly), whereas an increase in signaling either through activating 
mutations in GDF5 or through loss of function mutations in the inhibitor Noggin results in joint 
fusion (symphalangism) (Mundlos, 2009; Figure 44). GDF5-induced isolated brachydactylies are 
characterized by the relative preservation of the ring finger: it could be due to the highest p-SMAD 
activity in this finger, which permits a residual signaling via BMPs when GDF5 is mutated (Al-
Qattan, 2014). 
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Figure 44. Schematic diagram of BMP pathway and its modulators that control digit and joint development (Mundlos, 2009). 
 
A GDF-5 monomer consists of an N-terminal signal peptide domain, a prodomain and the C-
terminal mature part containing six highly conserved cysteine residues forming the cystine knot 
motif, whereas the seventh cysteine connects two monomers via an intermolecular disulfide bond.  
Single nucleotide polymorphisms (SNPs) in 5’ and 3’ UTR regions of the gene are associated with 
osteoarthritis (Valdes et al., 2012); mutations within the prodomain are typically frameshift 
mutations that prevent the production of an active protein and may be subclassified into two 
subgroups according to zygosity; mutations within the active (mature) domain and within the 
cleavage area (between the prodomain and active domain) are usually amino acid substitutions that 
can impair GDF5 function in many ways, causing a variety of phenotypes (Al-Qattan et al., 2015; 
Figure 45).  
 
                        
 
Figure 45. Genotype–phenotype correlations in the GDF5 mutational spectrum (Al-Qattan et al., 2015). 
 
Mutations along the whole sequence of GDF5 are known to cause in a heterozygous or 
homozygous state Brachydactyly type A1, C (OMIM #615072) (Byrnes et al., 2010), Brachydactyly 
type A2 (OMIM #112600) (Kjaer et al., 2006; Plöger et al., 2008; Schwaerzer et al., 2012; 
Seemann et al., 2005), Brachydactyly type C (OMIM #113100) (Al-Qattan et al., 2015; Everman et 
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al., 2002; Galjaard et al., 2001; Polinkovsky et al., 1997; Savarirayan et al., 2003; Schwabe et al., 
2004; Seo et al., 2013; Stange et al., 2014; Stange et al., 2015; Stavropoulos et al., 2016; Travieso-
Suárez et al., 2018; Ullah et al., 2018; Uyguner et al., 2014; Yang et al., 2008), Multiple synostoses 
syndrome 2 (OMIM #610017) (Dawson et al., 2006; Schwaerzer et al., 2012; Seemann et al., 2009), 
Symphalangism, proximal, 1B (OMIM #615298) (Wang X et al., 2006; Yang et al., 2008), Grebe 
chondrodysplasia (OMIM #200700) (Al-Yahyaee et al., 2003; Basit et al., 2008; Costa et al, 1998; 
Faiyaz-Ul-Haque et al., 2002a; Faiyaz-Ul-Haque et al., 2008; Martinez-Garcia et al., 2016; 
Mumtaz et al., 2015; Umair et al., 2017), acromesomelic dysplasia Hunter-Thompson type (OMIM 
#201250) (Thomas et al., 1996) and Du Pan syndrome (OMIM #228900) (Douzgou et al., 2008; 
Faiyaz-Ul-Haque et al., 2002b; Szczaluba et al., 2005).   
p.Leu53Profs*41 is a frameshift duplication located in the prodomain of GDF5 protein, which 
creates a premature stop codon 41 codons downstream of duplication, resulting in a truncated 
protein product comprising only of 92 amino acids. It results in loss of function of the GDF5 
protein (Umair et al., 2017).  
The variant has been already associated with brachydactyly type C in a heterozygous state 
(Everman et al., 2002) and with Grebe chondrodysplasia in a homozygous state (Umair et al., 
2017). The identification of this variant was important for genetic counselling as it could be 
hypothesized that it is causative of a mild phenotype, i.e. limb anomaly, in heterozygous state, but 
also of a very severe phenotype, characterized by severe abnormality of the limbs and limb joints, in 
a homozygous state. 
 
5.3 Families C and D 
 
The corpus callosum (CC) is the largest white matter tract in the human brain, containing about 200 
million axons that connect the left and right cerebral hemispheres (Aboitiz and Montiel, 2003). It is 
one of the five main cerebral commissures, which are bundles of nerve fibres that cross the midline 
of the human brain at the level of their origin. The others are the anterior, posterior, hippocampal 
and habenular commissures (Palmer and Mowat, 2014). The corpus callosum starts to develop at 
approximately 8 weeks of gestational age in humans and it is completely developed at 18-19 weeks, 
although further maturation and growth continue into postnatal life (Craven et al., 2015; Figure 46).  
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Figure 46. T1-weighted sagittal MRI scans showing the structure of the normal human corpus callosum in the full-term infant (A), 8-month-old (B), 
2-year-old (C), 8-year-old (D) and adult (E) (Edwards et al., 2014). 
 
Functionally, the corpus callosum permits not only the information transfer between cerebral 
hemispheres, but also the inhibition of concurrent activity in the contralateral hemisphere (Ozyüncü 
et al., 2014). Defects of the corpus callosum development can lead to different form of dysgenesis: 
this term refers to the CC being present but malformed in some way. Agenesis of the corpus 
callosum (ACC) is one of the most common congenital brain anomalies, with an estimated 
prevalence ranging from 1.8 per 10,000 in the general population to 230–600 per 10,000 in children 
with neurodevelopmental disabilities (D'Antonio et al., 2016). It results from failure of 
commissuration and implies that the entire structure has failed to form.  
ACC is a clinically and genetically heterogeneous condition, which can be observed either as an 
isolated phenotype or as a manifestation in the context of an autosomal-dominant, autosomal-
recessive or X-linked syndrome, as, for example, Apert syndrome (OMIM #101200), Miller–Dieker 
syndrome (OMIM #247200), Mowat–Wilson syndrome (OMIM #235730), Rubinstein–Taybi 
syndrome (OMIM #180849), Joubert syndrome (OMIM #608629), Walker–Warburg syndrome 
(OMIM #236670) and Opitz GBBB syndrome (OMIM #300000). Several causative mutations have 
been identified so far. In addition, ACC has been observed in constitutional trisomies as well as in 
some chromosomal rearrangements (Schell-Apacik et al., 2008).  
Hypoplasia of the corpus callosum consists, instead, in the partial failure of the corpus callosum 
development: the CC is thinner than normal, but with a regular anterior-posterior extent (Craven et 
al., 2015). This phenotype can be isolated or associated with a syndrome. Also other abnormalities 
of the CC, as its hyperplasia, have been noted in a variety of neurodevelopmental conditions 
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(Palmer and Mowat, 2014). 
 
The family C is composed of two generations: the proband is a 4-year-old girl affected by corpus 
callosum hypoplasia and growth and speech delays, daughter of a healthy Italian mother and a 
healthy Chinese father; the proband has a healthy sister; the fetus from a previous interrupted 
pregnancy was female and showed corpus callosum agenesis and other severe malformations.  
To find the cause of these recurrent corpus callosum phenotypes in the family, we performed a trio 
based clinical exome sequencing approach and we identified a supposed de novo nonsense variant 
in ARX gene (NM_139058.2: c.922G>T; NP_620689.1: p.Glu308*) in the proband.  
ARX gene is on the X chromosome and encodes a transcription factor, which contains one 
homeobox and one aristaless domain. It is highly expressed in gonads and brain, but also in 
pancreas and skeletal muscle. ARX is a homeobox-containing gene critical for early development 
and formation of a normal brain (Kitamura et al., 2002; Ohira et al., 2002; Strømme et al., 2002). It 
plays a vital role in telencephalic development, specifically in tangential migration and 
differentiation of GABAergic and cholinergic neurons (Colasante et al., 2009; Colombo et al., 
2007; Friocourt et al., 2008; Kitamura et al., 2002; Lee K et al., 2014). 
 
                             
 
Figure 47. Schematic representation of the human ARX protein (Mattiske et al., 2017). 
 
ARX contains multiple domains that include four polyalanine (pA) tracts (Figure 47), the first two 
of which are frequently expanded by mutations (Fullston et al., 2011).  
ARX is known to cause a broad spectrum of CNS disorders, including Epileptic Encephalopathy, 
Early Infantile, 1 (EIEE1; OMIM #308350), hydranencephaly or lissencephaly with abnormal 
genitalia (OMIM #300215), Partington syndrome (OMIM #309510), Proud syndrome (OMIM 
#300004) and intellectual disability (OMIM #300419). 
Mutations in this gene typically result in families with affected males across multiple generations 
transmitted via (usually) asymptomatic carrier females. However, there is an increasing prevalence 
of reported mutations in ARX that result in lissencephaly with abnormal genitalia (XLAG) in male 
patients and in variable and milder forms in females (Ekşioğlu et al., 2011; Kato et al., 2004; 
Kitamura et al., 2002; Marsh et al., 2009; Scheffer et al., 2002; Strømme et al., 2002). In these 
	 66	
familial cases the mutations are either missense mutations of residues in the homeodomain or 
nonsense/deletion mutations resulting in a loss-of-function of the ARX homeodomain and/or 
aristaless domain activity. A smaller number of de novo cases also result in truncation and loss of 
ARX function (Bettella et al., 2013; Kwong et al., 2015; Marsh et al., 2009; Wallerstein et al., 
2008), but the type and the location of mutations in affected females are restricted compared with 
those in affected males. Across these cases, there is a consistent phenotype of intellectual disability 
(ID) and/or developmental delay, infantile seizures and hypotonia/dystonia/ataxia (Mattiske et al., 
2017; Figure 48). 
 
                     
Figure 48. Identified ARX mutations in females and males leading to a range of phenotypes (modified from Mattiske et al., 2017). 
 
The nonsense p.Glu308* variant leads to the production of a truncated protein, lacking in the 
homeobox domain, and is predicted to be very deleterious using CADD scoring system. It is not 
reported in gnomAD; it was recently annotated in ClinVar (ID 522170) as pathogenic. Segregation 
analysis disclosed the presence of the same variant also in the fetus of a previous pregnancy with a 
more severe phenotype, which could be supposedly due to the concomitant presence of a de novo 
microduplication of a region on chromosome 17. The presence of the same mutation on both the 
affected fetus but not in the healthy parents suggests a gonadal or gonosomal mosaicism in one of 
the parents. The identification of this variant was important for genetic counselling as there is an 
increased recurrence risk for the couple to have a child with the same disorder. The identification of 
the causative mutation is of importance also for the proband not only for clinical prognosis but also 
as it allows to proper calculate the risk to transmit the mutation, which is associated with different 
clinical outcomes depending on the sex. 
 
The family D is composed of two generations: the proband (II:2) is a fetus with corpus callosum 
agenesis and other severe malformations; a previous pregnancy was interrupted because of a male 
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fetus with the Dandy-Walker syndrome (OMIM %220200) and hydrocephalous. 
To investigate the molecular bases of the phenotype in this family, we performed WES of the fetus 
and we identified a homozygous variant in FKTN gene (NM_006731.2: c.898G>A; NP_006722.2: 
p.Gly300Arg; rs909129168).  
FKTN gene is ubiquitously expressed, but in particular in the central nervous system. This gene 
encodes a putative transmembrane protein that is localized to the cis-Golgi compartment, where it 
may be involved in the glycosylation of α-dystroglycan in skeletal muscle (Figure 49); it is a 
glycosyltransferase with a role also in brain development.  
 
                         
 
Figure 49. O-mannosyl-Linked Glycosylation of DG in a Complex of Dystrophin-Associated Proteins (Montanaro and Carbonetto, 2003). 
 
The dystrophin-glycoprotein complex (DGC) is a multisubunit complex that connects the 
extracellular matrix components (ECM) to the cytoskeletal matrix of muscle fiber cells and 
maintains muscle integrity. Mutations in this complex are associated with muscular dystrophy. 
Although the role of dystroglycan has been explored mainly in the context of muscle, recently a 
novel role for dystroglycan inside the CNS has been demonstrated and thus provides potential 
insights into the brain abnormalities associated with some forms of muscular dystrophy, as the α-
Dystroglycanopathies (α-DGP), a group of muscular dystrophy characterized by abnormal 
glycosylation of α-dystroglycan (α-DG) (Montanaro and Carbonetto, 2003). 
Secondary dystroglycanopathies are caused by mutations in different genes, coding for putative or 
actual glycosyltransferases: POMT1, POMT2, POMGNT1, LARGE, FKTN and genes coding for 
fukutin-related proteins (FKRPs). Irrespective of the gene defect, the characteristic and diagnostic 
feature of all of these conditions is hypoglycosylation of α-dystroglycan, which led to the term 
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dystroglycanopathies for this group of disorders (Waite et al., 2012). 
 
                   
 
Figure 50. Model showing the effects of dystroglycan hypoglycosylation on neuronal migration in the developing cortex (Waite et al., 2012). 
 
During development, neuronal progenitors migrate radially out of the ventricular zone (VZ) along 
radial glial cells. Hypoglycosylation or deletion of a-dystroglycan disrupts the interaction between 
a-dystroglycan and ECM proteins such as laminin-a1. This may lead to DGC destabilization on 
radial glial cells. Overmigrating neurons in the developing cortex cause breaches in the glia limitans 
(GL) leading to neuronal and glial heterotopias and disordered lamination of the cerebral cortex. In 
some dystroglycanopathy models, the composition of the basal lamina (BL) is also altered (Waite et 
al., 2012; Figure 50). 
FKTN gene is known to cause different recessive disorders: Walker–Warburg syndrome (WWS) or 
muscle–eye–brain disease (MEB) or Fukuyama congenital muscular dystrophy (FCMD) or 
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 
(MDDGA4) (OMIM #253800), Cardiomyopathy, dilated, 1X (CMD1X; OMIM #611615), 
Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4 
(MDDGB4; OMIM #613152) and Muscular Dystrophy-Dystroglycanopathy (limb-girdle), type C, 
4 (MDDGC4; OMIM #611588).  
The variant p.Gly300Arg is not annotated in gnomAD database; it is reported in dbSNP, without an 
associated frequency. The Glycine 300 is inside a very conserved region, in which two other 
patogenetic missense homozygous mutations have been described: p.Trp305Cys (NP_006722.2) 
associated with dystroglycanopathy type A4 (Godfrey et al., 2007; Yis et al., 2011) and 
p.Tyr306Cys (NP_006722.2) associated with limb-girdle muscular dystrophy (Riisager et al., 
2013). 
A structural analysis suggests that replacing Gly300 with an Arg residue is predicted to have steric 
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hindrance effects that abolish the activation of the sugar moiety. The latter activity is required for 
the glycosylation of α-dystroglycan in skeletal muscle. Thus, Gly300Arg is likely responsible for a 
reduced activation of the sugar moieties, which in turn impairs transfer to α-dystroglycan.  
Concurrently to whole exome data analysis, a fetal MRI (fMRI) performed at 18 weeks showed a 
marked dilatation of the ventricular system and a diffuse compression on cerebral parenchyma. The 
corpus callosum was absent and the cerebellum was markedly hypoplastic, with a severe reduction 
of the vermis. Differently from what was suggested by ultrasound analysis, the association of all 
these anomalies was consistent with the diagnosis of a more severe neurological phenotype, 
compatible with Muscular Dystrophy-Dystroglycanopathy Type A, confirming molecular results. 
The couple decided to terminate the pregnancy: the fetopsy confirmed the diagnosis.  
The identification of this variant was important for genetic counselling as it allowed to proper 
redefine the clinical diagnosis, with implications on recurrence risk for the couple and on 
reproductive choices.  
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6. CONCLUSIONS 
 
The main purpose of this PhD project was to find the most appropriate NGS technology and 
approach to study the molecular bases of different genetic diseases.  
The different choices regarding the NGS approach and the number of individuals to sequence were 
therefore dictated by the pedigree structure and the specific phenotype.  
These results demonstrate how the proper and accurate definition of the phenotype and the 
evaluation of diagnostic potential, feasibility and cost of each NGS approach can result in the 
efficient identification of new variants/genes underlying rare phenotypes. Applying NGS 
techologies also in the clinics will improve the diagnosis, the genetic counsellig and, potentially, at 
least in some cases, the treatment of genetic diseases.  
The lack of a diagnosis can have considerable adverse effects for patients and their families: failure 
to identify potential treatments, failure to recognize the risk of recurrence in subsequent pregnancies 
and failure to provide anticipatory guidance and prognosis. NGS may improve patient health 
outcomes and facilitate the more efficient use of health-care resources: the “diagnostic odyssey”, to 
which patients are often subjected without receiving a diagnosis, has implications for societal 
medical expenditures, with unsuccessful attempts consuming limited resources. The application of 
NGS to clinical diagnosis raises a lot of challenges, but it is revolutionizing medical genetics and 
leading us to the personalized medicine. 
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